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ABSTRACT 
 
The feed conversion efficiency can be improved through increasing the ratio of 
lean to fat deposition in animal. The benefits of this involve decrease production costs, 
increase produce quality, reducing grazing pressure and decreasing nitrogenous 
excretion into the environment. Since beta agonists and growth hormone result in 
muscle fibre hypertrophy and changes in muscle fibre type composition, also promote a 
rise in muscle mass and abatement in fat, therefore there are good methods to increase 
the feed conversion efficiency. In order to improve feed conversion efficiency, the 
mechanisms of reaction need to be study.  
 
For this project, the aim is to identify growth signaling pathways in skeletal 
muscle. Since an appropriate sheep-specific microarray was unavailable, a human 
affymetric arrary and genomic DNA hybridization were used to investigate effects of 
BA and GH on the sheep muscle transcriptome. Microarray data was analyzed using 
Ingenuity Pathway Analysis software and GeneSpring. The microarray analysis results 
were conformed by real-time quantitative RT-PCR.  
 
As the results of this project, there were some target genes and signaling pathways 
had been identified, these included AKT1 pathway and PSAT1 pathway which 
associated with protein synthesis; and citrate cycle pathway, oxidative phosphorylation 
pathway and glycolysis pathway which correlated with energy metabolism. These 
pathways were predominantly associated with beta-agonists response in comparison 
there were only relatively minor effects of growth hormone.  
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1. INTRDUCTION 
 
1.1Background  
 
In today's world, the control of lean and fat tissue deposition in the meat of 
livestock is a very popular and welcomed subject for producers, consumers and 
environmentalists. If the ratio of lean to fat deposition in animal is improved, the feed 
conversion efficiency will be improved at the same time. The cost of feed determines 
the quantity of profit, so raising feed conversion efficiency (FCE) is very important for 
producers. Besides this, in many countries of South East Asia, with the increased 
economy and population, the meat demand and feed supply of livestock are also 
increased. This make a heavy pressure effecting the whole world. If the FCE is 
improved, more meat can be supplied to people currently with limited resources. Last 
but not least, FCE is important because increase FCE is good for reducing 
environmental pressure and decreased nitrogenous excretion into atmosphere (Coffey, 
1996; Sillence, 2004). A lot of lamb producers also pay close attention to the feed 
conversion efficiency, even if their production relies on grazing to a great extent. For 
these lamb producers, increasing feed conversion efficiency is a good method to 
improve meat production and at the same time reduce the pasture pressure on the 
affluent, but fragile natural landscapes (Hunter et al., 1993). However, finding a method 
to complete these aims that is affordable, acceptable and also reliable, to the vast 
majority person has demonstrated to be one great challenge for the researchers and 
producers. 
 
Since the European Union forbade hormonal growth promoters about fifteen years 
ago, some countries such like the United States and Australia got new license to 
produce domestic animal production. The new license ind icates that beta adrenergic 
agonist, bovine growth hormone, porcine growth hormone and equine growth hormone 
can be used into livestock production (Sillence, 2004).  
 
The producers consider how to improve their produces, while the researchers 
study how to develop the novel technologies. Opportunities to develop beta adrenergic 
agonist consist of reducing the effects of meat toughness, decreasing bad influences on 
treated livestock, and lengthening the time of action. It is noteworthy that the jointed 
use of the bate-agonist with growth hormone, which can up-regulates beta 
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adrenoceptors, can bring an significant improvement in feed efficiency and carcass 
composition (Sillence, 2004). In endocrinology, another outstanding improvement is 
that the hormones, which are secreted by fat and muscle cells, adjust energy 
metabolism, body composition and feed intake. By researching double-muscled or 
genetically obese livestock, adiponectin, myostatin and leptin have been found. 
$OWKRXJK WUDQVJHQLF OLYHUVWRFN¶VSURGXFWLRQ is still effected by the low level control of 
gene expression, and also challenges to the acceptance of the consumer, these results 
can be exploited potentially though genetic management.  
 
Because the beta agonists (BA) and growth hormone (GH) can promote a rise in 
muscle mass and abatement in fat, therefore there are good methods to increase the feed 
conversion efficiency (Enright, 1989; Buttery and Dawson, 1990). The beta agonists 
and growth hormone have different ways to reach this goal. GH principally indirectly 
affects is though insulin- like growth factor 1 (IGF-SURGXFWLRQµVVWLPXODWLRQ6FDUWK
2006). However, as Lynch and Ryall explained (2008) that beta agonists is trend to 
directly effect via beta-DGUHQHUJLF UHFHSWRUV ȕ-ARs). Lefaucheur and Gerrard pointed 
out (2000) that the efficacy of BA and GH in changing muscle mass trended to depends 
on the composition of fibre type and/or the transitions of muscle fibre type.  
 
1.2Skeletal muscle function and metabolism 
 
As skeletal muscle makes movement, it is an important part of the body and play a 
principal role in metabolism (Lawrence and Fowler, 2002). The interaction of myosin 
and actin, dominated by the binding of calcium ions to troponin-C (a kind of protein 
has relation with actin filaments) is thH UHDVRQ RI WKH PXVFOH¶V FRQWUDFWLRQ )UD\Q
2003). Adenosine triphosphate (ATP) can supply energy for muscle contraction, and it 
can be hydrolyzed to inorganic phosphate (Pi) and adenosine diphosphate (ADP). 
Through aerobic or anaerobic metabolism, the different substrates can be used to create 
adenosine triphosphate (Frayn, 2003). Besides this, skeletal muscle action as the amino 
DFLGV¶VWRUDJHFDQEHXVHGIRUJOXFRQHRJHQHVLVDQGWKHV\QWKHVLVRIGHQRYRSURWHLQDQG
has a main role in glucose regulation, it store as glycogen (Lawrence and Fowler, 2002; 
Frayn, 2003). The contraction of muscle and substrate utilization are displayed in 
Figure 1.1. 
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Figure 1.1 Skeletal muscle contraction and substrate utilization pathways (Flück and 
Hoppeler, 2003) 
An action at the neuromuscular junction leads to depolarisation of the T-tubules, which in turn 
activates calcium ions release from sarcoplamic reticulum into the cytoplasm. Calcium ions binds to 
troponin, this permitting the interaction of actin with myosin, and subsequent shortening of 
sarcomere. This excitation contraction process depends on adenosine triphosphate. The creatine and 
arginine ATP storages provides the initial adenosine tr iphosphate. Then glycolysis supplies 
adenosine triphosphate efficiently. Whereas the lactate production effects the performance of muscle 
and the glycolysis is inefficient with that. Hence for prolonged muscle contraction ATP is generated 
E\FDUERK\GUDWHPHWDEROLWHVDQG WKHIDWW\DFLG¶VPLWRFKRQGULDOR[LGDWLRQ7KH LQWUDFHOOXODU VWRUDJHV
and blood can provide substrates. After the cessation of an action, the potential calcium ions are 
pumped into sarcoplasmic reticulum.  
 
1.3Growth promoting agents and muscle fibre type 
 
1.3.1Growth promoting agents 
 
Recently the control of lean and fat tissue deposition in the meat of livestock is a 
very welcomed topic for many people. An increase of the lean to fat tissue deposition 
can lead to an improvement of the meat production of every animal, this always 
correlates with the improvements of feed conversion efficiency (FCE). Methods for 
adjusting lean and fat tissue deposition in the meat include using growth promoting 
agents, such as beta agonists (BA) and growth hormone (GH).  
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Beta-agonists can promote the meat growth of livestock and increase the 
proportion of protein (Lynch and Ryall 2008). The beta-DJRQLVWV¶DQDEROLF LQIOXHQFH LV
highly selective for skeletal muscle compare with other growth promoters 
(Sillence,2004). If the protein of intake is restricted, the effect of it should reduce. 
However, even the underfed animals show an effect, because beta-agonists can 
redistribute protein from other tissues to skeletal muscle (Sillence 2000). Therefore, 
beta-agonists are also called repartitioning agents.  
 
Growth hormone can decrease body fat of livestock, while increasing muscle mass 
(Sillence,2004). The growth hormone receptors (GHRs) of target organs have a very 
important role in the whole growth process. The functions of GH have been 
demonstrated in two ways. FirstˈGH effects target organs, like liver, binding to GHRs 
and producing insulin- like growth factors (IGFs). Then IGFs go into the blood and bind 
to insulin- like growth factor binding proteins (IGFBPs). They arrive to target organ and 
act on insulin- like growth factor receptors (IGFRs), thereby regulating growth and 
development. Second, GH can directly affect target organs, like muscle, to produce IGF 
through paracrine or autocrine to adjust the growth and development (Scarth, 2006).  
 
These two growth agents can increase fat and muscle mass, however their effects 
have different action mechanisms (Figure 1.2). Beta-agonists exert this effect primarily 
directly via ȕ-ARs, while growth hormone expresses this effect through stimulating 
liver to produce IGF-1. Then IGF-1 can bind to aim tissues (Bell et al., 1998). It is 
worth to note that signaling pathways of them appear a overlap part, which is 
phosphoinositol 3-kinase (PI3K) pathway. 
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Figure 1.2: Growth hormone and Beta-agonists signalling pathways. (Glass 2003; 
Chang 2007 and Lynch and Ryall 2008)  
This figure shows the signalling pathways correlated with beta-agonists and growth hormone 
administration. The effects form Growth hormone are primarily exerted by IGF-1, then IGF-1 acts 
on tyrosine kinase receptors of muscle. The effects form Beta-agonists primarily via acting on 
ȕ-$5¶VGLUHFW  
 
4EBP1 - eIF4E Binding Protein 1, cAMP-Cyclic adenosine monophosphate, CREB - cAMP 
response element binding protein. eIf2B - Eukaryotic translation initiation factor 2B, eIf4E ± 
Eukaryotic Translation Initiation Factor 4E, Epac - Exchange protein activated by cAMP, ERK - 
Extracellular-Signal-Regulated Kinase, FOXO - forkhead box, sub-group O, GS - Glycogen 
Synthase, GSK3 - Glycogen Synthase Kinase-3HDAC5 - Histone deacetylase 5, IRS-1 - Insulin 
Receptor Substrate-1,MAFbx - Muscle Atrophy F-box, MEK - Mitogen-Activated Protein 
Kinase/ERK Kinase, mTOR - Mammalian Target of Rapamycin, MURF1 -Muscle-Specific RING 
Finger 1, p70s6K - 70 kDa Ribosomal Protein S6 Kinase 1, PI3K - Phosphoinositide 3-Kinase, PIP2 
-Phosphatidylinositol 4,5-Bisphosphate, PIP3 - Phosphatidylinositol 3,4,5-Trisphosphate, PKA - 
Protein Kinase A, Rap 1 - repressor activator protein, SIK1 - salt-inducible kinase 1,  
 
1.3.1.1 Growth hormone 
 
The anterior pituitary is responsible for secreting growth hormone into blood, then 
stimulates and produces IGF-1 in liver (mainly). Growth hormone also has a direct 
influence on some target tissues, for example, adipose tissue is stimulated direct by 
growth hormone to produce IGF-1 (Scarth, 2006). Then IGF-1 acts on many cell types 
LQ WKH ERG\¶V LQGLYLGXDO WLVVXHV )LJXUH  GLVSOD\V WKH SDWKZD\V UHODWH WR VNHOHWDO
 14 
muscle cells. IGF-1 acts on tyrosine kinase receptors, this leads to IRS-¶VUHFUXLWPHQW
then the signals are sent to mitogen activated protein kinase  and phosphoinositide 
3-Kinase (PI3K) pathways (Glass, 2003). This makes the muscles trend to hypertrophic 
and/or hyperplastic growth and this process depends on the muscle development stage.  
 
1.3.1.2 Beta-agonists 
 
Murdoch et al (2006) pointed out that adrenergic receptors adjusted the influences 
of physiological agonists. The catecholamines, including noradrenaline, dopamine and 
adrenaline, are released in times of stress and under other metabolic challenges. 
Adrenaline and noradrenaline stimulate glycogenolysis in liver and muscle, lipolysis in 
adipose cell and gluconeogenesis in liver (Gerrard and Grant, 2006), hence releasing 
the energy reserves of body, correlated with the demand for a raise in energy consume 
(Murdoch et al., 2006). In skeletal muscle, ȕ-AR stimulation also changes the protein 
WXUQRYHU¶V UDWH OHDGV SURWHLQ GHSRVLWLRQ VXFK DV JURZWK 15&  )LJXUH
6KRZV WKH VLJQDOOLQJ SDWKZD\V RI FHOOV HGXFLQJ WKH ȕ-AR mediated influences on 
VNHOHWDO PXVFOH 7KH ȕ-$5¶V VWLPXODWLRQ OHDGV WR a conformational variation in the 
FRUUHODWHG * SURWHLQ JXDQRVLQH GLSKRVSKDWH LV GHYROYHG IURP WKH Į VXEXQLW DQG
JXDQRVLQH WULSKRVSKDWH ELQGV 7KLV OHDGV WR WKH Į VXEXQLW GLVVRFLDWLQJ IURP WKH ȕȖ
VXEXQLWV 7KH Į VXEXQLW WKHQ VWLPXODWHV DGHQ\O\O F\FODVH WR produce cAMP, which 
PHGLDWHVGRZQVWUHDPHIIHFWVWKHQ WKHDGHQ\O\OF\FODVH LVVWLPXODWHGE\ĮVXEXQLWDQG
bring cAMP, which can adjusts the effects of downstream, the most well characterized 
being PKA pathway. The PI3K pathway can be activated by remaininJȕRUȖVXEXQLW
(Lynch and Ryall, 2008). 
 
1.3.2Muscle fibre type 
 
The muscle is according as shortening velocity to class as fast and slow-twitch 
muscles (Scott et al., 2001). Based on the metabolic and contractile properties of 
muscles, muscle fibres also can been classified (Figure 1.3). The contractile muscle 
ILEUH W\SH DFFRUGLQJ WR WKH GLVWLQFW P\RVLQ KHDY\ FKDLQ LVRIRUPV¶ H[SUHVVLRQ DQG
muscle fibre types are always named based on the myosin heavy chain (MHC) isoforms 
expressed in them (Lefaucheur and Gerrard, 2000). Thereby fast fibres can express the 
IIA or IIX or IIB MHC isoforms, while slow fibres just can express type I myosin 
KHDY\FKDLQLVRIRUP)LEUHW\SHVDUHDOVRUHOHYDQWWRWKHILEUH¶VPHWDEROLFFDSDFLW\7KH
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metabolic capacity of fibre is an entia across muscle fibre types, and with all of the 
fibre types having an entia of glycolytic and oxidative metabolism, whereas every fibre 
type owns a distinct capacity for every kind of metabolism (Gerrard and Grant, 2006).  
 
Figure 1.3: 6NHOHWDOPXVFOHILEUHW\SHV¶FKDUDFWHUL]DWLRQEDVHGRQPHWDEROLFDQG  
contractile features (Gerrard and Grant, 2006) 
In this figure, red means slow-twitch muscles and white means fast-twitch muscles.  
 
1.3.3Growth promoting agents and the relationship with muscle fibre 
type 
 
The responses of muscle hypertrophy to growth promoting agents may depend on 
the muscle fibre types or include the changes of fibre type compo sition. Growth 
KRUPRQH WUHQGV WRULVH DOORI ILEUHV¶FURVVVHFWLRQDODUHD &6$ KRZHYHUQR LQIOXHQFH
on muscle fibre type composition (Lefaucheur and Gerrard, 2000).Whereas there was a 
human study indicated that a rise in myosin heavy chain IIX in response to growth 
hormone, hence growth hormone may also change fibre type (Lange et al. 2002). BA 
WUHQGVWRLQFUHDVHWKHIDVWILEUHV¶&6$.LPet al. 1987; Sainz et al. 1993). 
 
A recent experiment indicated that the growth promoters, particularly BA, induced 
muscle growth and this appeared to be a switch to a muscle type that was a fast type 
with an apparent reduction on the oxidative metabolic capacity (produced by Krystal 
Hemmings). 
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1.4Technology  
 
1.4.1Microarry analysis  
 
1.4.1.1What is microarry 
 
The microarray is a kind of miniature analytical installation that is used to the 
JHQRPLF H[SORUDWLRQ ,W KDV WKH KLJKHVW SUHFLVLRQ DQG VSHHG LQ WKH ELRORJ\¶ KLVWRU\  
These small glass chips which include tens of thousands of genes can be used to check 
the fluorescent samples. The messenger RNA (mRNA) of cells, tissues, organs and the 
other biological materials labels in the fluorescent samples (Figure 1.4). The 
IOXRUHVFHQWVDPSOHV¶PROHFXOHVUHDFWZLWKKRPRORJRXVVHTXHQFHVLQWKHFKLSWKLVOHDGV
every spot to shiQH ZLWK DQ LQWHQVLW\ ZKLFK SURSRUWLRQDO WR WKH H[SUHVVHG JHQH¶V
activity. The large capacity of this small device can analyze the whole human genome 
in one experiment. Since the gene expression is strongly related to function, microarrys 
can prove much information on disease, drug action, hormone action, diet, mental 
illness, aging and a lot of other clinical problems. Beside that, micrarrays can find the 
JHQH VHTXHQFHV¶ FKDQJHV SDYH D QHZZD\ IRU JHQHWLF VFUHHQLQJ JHQHWLF GLDJQRVWLFV
and genetic testing. Protein and tissue microarrys are abbreviated traditional 
biochemical and histological assays, quickening the analysis of protein-protein 
interactions, enzymes and tumor specimens. Because the microarrays can study the 
genomes of viruses, bacteria, worms, plants, fruit flies, primates, cows, mice, rats and 
FKLFNHQVLWLVFDOOHGWKHELRFKHPLVWU\¶V1RDK¶V$UN0DUN6FKHQD  
 
Figure 1.4 The process of microarrys analysis (Mark Schena, 2002) 
In the process of microarrys study, mRNA is isolated form sample cells, then labeled by f luorescent 
tags, and then hybridized WR WKHFKLSZKLFK LQFOXGHV WKHJHQHVHTXHQFH7KHIOXRUHVFHQWVDPSOHV¶
molecules react with homologous sequences in the chip, this leads every spot to shine with an 
intensity, which proportiRQDO WR WKH H[SUHVVHG JHQH¶V DFWLYLW\ 7KHVH LQWHQVLWLHV DUH FRGHG LQWR D
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color palette, which shows as horizontal bar in this figure. From every location of microarrys, the 
quantitative data of gene expression can be got by determining the intens ity of fluorescence. 
 
1.4.1.2Microarrays types and applications 
 
The microarrays have many types, that include DNA microarrays (like 
oligonucleotide microarrays, SNP microarrays and cDNA microarrays), MMChips (for 
surveillance of microRNA populations), tissue microarrays, protein microarrays, 
chemical compound microarrays, cellular microarrays (or transfection microarrays), 
carbohydrate arrays (or glycoarrays) and antibody microarrays  
(http://en.wikipedia.org/wiki/Microarray). In this project, the DNA microarrays 
(Affymetrix-GeneChip) had been used. The applications of the DNA microarrays 
showed in Table 1.1 (http://en.wikipedia.org/wiki/DNA_microarray).  
 
Table 1.1 The applications of the DNA microarrays 
Application technology Synopsis 
Gene expression profiling 
In a gene expression profiling or mRNA experiment, the 
WKRXVDQGV RI JHQHV¶ expression levels are monitored 
together to research the influences of certain diseases, 
treatments and developmental process on gene expression. 
For instance, people can use microarray-based gene 
expression profiling to study the genes whose expression is 
changed in response to other organisms or pathogens 
through comparing gene expression in uninfected to that in 
infected tissues or cells (Adomas. et al, 2008).  
Comparative genomic 
hybridization 
Estimating genome content in closely related organisms or 
in different cells (Pollack et. al. 1999; Moran et.al.2004).  
Gene ID 
6PDOOPLFURDUUD\VWRGHWHFWRUJDQLVPV¶,'VLQIHHGRUIRRG
for example, GMO (Kulesh et al 1987), pathogens for 
disease detection or mycoplasms in cell, mainly combining 
microarray technology and PCR. 
Chromatin 
immunoprecipitation on 
Chip 
DNA sequences bind to a special protein that can be 
isolated by immunoprecipitating the protein, these 
fragments hybridizes to a microarray permitting the 
determination of protein binding site occupancy throughout 
the genome. For instance, the protein to immunoprecipitate 
are RNA Polymerase II to research transcription landscape 
or histone modifications (H3K9me3, H3K27me3, 
H3K4me2, etc.), trithorax-group protein (Ash1) and 
Polycomb-group protein (PRC1:YY1, PRC2:Suz12) to 
research the epigenetic landscape. 
Dam ID 
Genomic regions bound by an interesting protein can be 
separated and used to hybridize a microarray to define 
binding site occupancy. Dam ID is different form ChIP, it 
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does not need antibodies, however it uses adenine 
methylation close to the protein's binding sites to amplify 
those regions, introduced through expressing minute 
quantity of interesting protein combined to the DNA 
adenine methyltransferase of bacterium. 
SNP detection 
Detection single nucleotide polymorphism in alleles within 
SRSXODWLRQV +DFLD HW DO  0LFURDUUD\V¶ several 
applications use SNP detection, involving forensic 
analysis, genotyping, determining drug-candidates, 
surveying predisposition to disease, assessing body 
mutations in cancers or germline mutations in individuals, 
analyzing genetic linkage or evaluating loss of 
heterozygosity. 
Alternative splicing 
detection 
The design of an exon junction array uses probes particular 
to the predicted exons¶ SRWHQWLDO VSOLFH VLWHV ,W LV RI
intermediate coverage, or density, to a genomic tiling array 
(with thousands or hundreds of probes each gene) and a 
classical gene expression array (with 1 to 3 probes each 
gene). ,W FDQ EH XVHG WR WHVW DOWHUQDWLYH VSOLFH IRUPV¶
expression. Exon arrays have a distinct design, using 
probes designed to test every individual exon for predicted 
or known genes, and also can be utilized for exploring 
splicing isoforms. 
Fusion genes microarray 
A Fusion gene microarray can explore fusion transcripts, 
for example, from cancer specimens. The principle is 
building on alternative splicing microarrays. Oligo design 
method PDNHV FKLPHULF WUDQVFULSW¶V FRPELQHG
PHDVXUHPHQWV MXQFWLRQV ZLWK LQGLYLGXDO IXVLRQ SDUWQHUV¶
exon-wise measurements. 
Tiling array 
Genome tiling arrays is composed by overlaying probes 
designed to densely show a genomic interesting region, 
sometimes as big as one whole human chromosome. The 
aim is to explore empirically expression of alternatively 
splice forms or transcripts which may unknown. 
 
1.4.1.3Cross-species microarray 
 
7KH JHQH H[SUHVVLRQ¶V PRGXODWLRQ UHSUHVHQWV WKH EDVLF PHFKDQLVP RI ELRORJ\
process underlining pathological derailments and physiological developments. The 
application of microarrays to explore all of the transcriptional profiles is a widely used 
and valuable tool for studying biological systems, containing the disease responses and 
developmental processes, and it also can provide significant new ideas into the 
ELRORJLFDO SURFHVV¶V PROHFXODU PHFKDQLVPV %URZQDQG %RWVWHLQ /RFNKDUW DQG
Winzeler 2000). Although microarray improves greatly the genetic analysis in 
biological systems, however because this powerful technology has been primarily 
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restricted to a few model animals, plants and human. To make high-density DNA 
microarrays have to spend a lot of money and time. This method includes ranking the 
gene transcripts on a big scale from different tissues, classing the expressed sequence 
tags (ESTs) to produce special transcripts, annotating these transcripts, probe design, 
and synthesizing these probes on glass chips. Therefore, people would like to find a 
new method to avoid this large undertaking and use existing microarray to do 
cross-species transplant. 
 
Recently, some researchers pointed out that all of the mammalian own a common 
ancestor before more or less 65 to 100 million years (Lewin, 1999). The protein 
IXQFWLRQV¶SUHVHUYDWLRQSOXVQRWORQJWLPHVSDQR f the geology result that a high quality 
of nucleotide sequence has been saved in mammalian species. The sequences of human 
and 2820 orthologous rodent have been compared by Makalowski and Boguski in 1998, 
the result shows that these two far related mammals have a large resemblance in their 
gene transcripts. They pointed out that, between mouse and human, average identity is 
85.9 percent in protein-coding nucleotide VHTXHQFHV LQ ¶-untranslated region is 71.0 
SHUFHQWDQGLQ¶-untranslated region is 69.7 percent. 
 
In 2004, Ji. et al. used cross-species hybridization with human high-density 
oligonucleotide arrays (Affymetrix GeneChip) to study far related mammals species: 
SLJGRJDQGFDWWOH%DVHGRQWKH$II\PHWUL[*HQH&KLS¶VVSHFLDO IHDWXUHWKDWHDFKJHQH
is embodied by more than one probes, they hypothesized the sequence conservation of 
mammals is sufficient strong to bring enough signals from some probes for gene 
expression analysis. They proved that although all of the hybridization signals were low 
in the cross-species hybridization experiment, a spot probes of the majority of genes 
still brought signals. The finally result was same as same-species hybridization. It 
showed that it was possible to use cross-species hybridization to study other mammals 
for which species-specific microarrays are not available, but that not all probes worked. 
Recently, the researchers agree widely that the cross-species method can be used to 
research the sample do not has accomplished genome arrays (Chismar et al., 2002; 
Higgins et al., 2003; Spiewak and Gerin, 2004; Khaitovich et al., 2004; Hammond et al., 
2005, 2006; Bar-Or et al., 2007; Broadley et al., 2008). Since current available sheep 
microarrays are more targeted to study genes involved in immune response, not suitable 
for studies on muscle growth and metabolism. And also the ovine does not have 
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accomplished genome arrays available. Hence, for this project the sheep RNA had been 
hybridized by human microarry.  
 
1.4.2Software analysis 
 
1.4.2.1GeneSpring 
 
GeneSpring is a kind of powerful software that can provide accessible statistical 
tools and professional analysis of genomic structural variation and expression data. The 
core features of transcriptomics applications of GeneSpring (as described in Agilent 
GeneSpring GX user manual 2009) include: First, Gene- level expression analysis on all 
the microarray platforms, including Affymetrix, Illumina and Agilent. Second, using 
intact TargetScan information to analyze microRNA and identify gene targets. Third, 
can be applied to analyze Real-time PCR data. Fourth, NCBI Gene Expression 
Omnibus Importer tool for expression datasets.  
(http://www.chem.agilent.com/en-US/products/software/lifesciencesinformatics/genesp
ringgx/Pages/default.aspx). 
 
For this project, the main functions of GeneSpring: profile plots analysis, 
statistical analysis, principal components analysis, gene ontology analysis, filtered on 
volcano plot, venn diagram analysis and pathway analysis had been used.  
 
1.4.2.2Ingenuity Pathway Analysis software 
 
The target genes which identified by GeneSpring had been analyzed by Ingenuity 
Pathway Analysis software (IPA version: 8.6-3003 Build: 93815;2010 Ingenuity 
Systems, Inc) to identify specific signaling pathways.  
  
IPA is a kind of powerful and web-based software that can provide 
bioinformaticians and biologists to identify a visualization of an underlying mechanism, 
specific biological signaling pathways and functions most correlative to genes of 
interest or experimental of researchers (Ganter and Corner, 2007). 
 
The IPA dynamically combines relevant biological functions and networks 
focused on the experimental interesting genes. Scientists can create new pathways for 
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specific biomarkers, targets, biological functions or disease areas. IPA gives researchers 
a deeper and more complete understanding of cellular and molecular mechanisms, 
which ultimately influences future experimental direction and improves experimental 
process (Alessia et. al. 2010; and www.ingenuity.com).  
 
IPA uses a manually management and robust database, ,QJHQXLW\¶V .QRZOHGJH
Base (IKB). It includes up-to-date information on more than 20,000 mammalian 
proteins and genes, over one hundred canonical pathways and 1.4 million biological 
LQWHUDFWLRQV7KH,QJHQXLW\¶V.QRZOHGJH%DVH LVVWUXFWXUHG LQWRDQRQWROR gy consisting 
of more than 60 thousands processes and objects, onto which inputted protein or gene 
identifiers are mapped to. IPA has many kinds of main functions that can help 
researchers to deeply analyze and understand data. First function, the IPA Core  
Analysis can provide biological processes and pathways that are most significant in the 
analyzed results. Second, the IPA Function Analysis associates biological diseases and 
functions to dataset. Third, the IPA Canonical Pathway Analysis can be used to identify 
the most relevant signaling and metabolic pathways among those present in up-to-date 
dataset. Fourth, the IPA Tox Analysis can analyze the particular proteins or genes are 
observably associated with important function genes based on present biological 
processes, toxicity lists and main toxicological responses. The finally score can be 
found in the sumarry lists (Alessia et.al. 2010). In the analysis of this project, the IPA 
Core Analysis had been utilized.  
 
1.4.3Quantitative real time polymerase chain reaction  
 
The another name of real-time polymerase chain reaction is kinetic polymerase 
chain reaction (KPCR) or quantitative real time polymerase chain reaction 
(qPCR/qrt-PCR/Q-PCR). It based on the traditional PCR, is a laboratory technique of 
molecular biology, can be used to amplify and synchronously quantify an aim DNA 
molecule. It can explore and quantify (relative amount when normalized to import 
DNA or as absolute copies number) the particular sequences in the target DNA 
molecule. The key feature of real-time polymerase chain reaction is amplified DNA is 
explored as a reaction progress called real time. It is a new method compared to 
traditional PCR. In real-time PCR, two common approaches for exploring products are:  
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(1) sequence-specific DNA probes is composed by oligonucleotides. A fluorescent 
sign labels with them, it only allows exploration which after the probe has been 
hybridized with its corresponding DNA sequence.  
(2) another one is non-specific fluorescent dyes, it intercalates with any 
double-stranded DNA.  
Normally, reverse transcription is integrated with real-time polymerase chain 
reaction to quantify Non-coding RNA and messenger RNA in tissues or cells.  
The abbreviations of real-time PCR can be Q-PCR, RTQ-PCR or qPCR 
(VanGuilder et al, 2008), RRT-PCR (Spackman and Suarez 2008), qRT-PCR (Udvardi 
et al.2008) or RT-rt PCR (Gertsch et.al.2002) often means real-time 
reverse-transcription PCR. RT-PCR normally means reverse-transcription PCR but not 
real-time PCR, however not all of the authors insist on this convention (Logan et. al. 
2009). 
1.4.3.1Real-time PCR with double-stranded DNA-binding dye  
 
The DNA-binding dye combines to all of the double-stranded DNA in PCR, 
FDXVLQJWKHG\H¶V IOXRUHVFHQFH'XULQJ3&5DULVH LQ'1$SURGXFWUHVXOWV LQDU ise in 
the intensity of fluorescence and is surveyed at every cycle, therefore permitting to 
quantify the DNA concentrations. Whereas double-stranded DNA (dsDNA) dyes (like 
SYBR Green) can bind to all of the double-stranded DNA PCR products, involving 
non-specific PCR products (for example, primer dimer). This may prevent or interfere 
ZLWKWKHWDUJHWVHTXHQFH¶VDFFXUDWHTXDQWLILFDWLRQ  
The process shows below: 
1. Usual reaction preparation added fluorescent double-stranded DNA dye. 
2. A Real-time PCR instrument (like Light Cycle 480) is responsible for running 
this reaction. The fluorescence levels are surveyed by a detector after every 
cycle. Only when the dye bind to dsDNA (like PCR product), the fluorescence 
has been shown. With reference to standard dilution, the double-stranded DNA 
concentration can be mensurated.  
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As explained above, comparing the determined RNA/DNA sample to the standard 
dilution will just provide a ratio or fraction of the RNA/DNA sample relevant to the 
standard, only permitting correlative comparisons between experimental condition or 
different tissues. In order to make sure the accuracy of quantification, it needs to 
QRUPDOL]H WKH WDUJHW JHQH¶V H[SUHVVLRQ WR D VWHDGLO\ H[SUHVVHG JHQH7KLV FDQ DPHQG
possible discrepancy in RNA quality or quantity across the samples of experiment 
( http://en.wikipedia.org/wiki/Real_time_PCR). 
In this project, the SYBR Green had been used to do Real Time PCR, in next part 
the principle of them will be explained.  
1.4.3.2SYBR Green principle 
 
SYBR Green is a kind of fluorescent dye that only can bind to double-stranded 
DNA. Fluorescence sent out proportionally to double-VWUDQGHG '1$¶V DPRXQW 7KH
input cDNA or DNA of PCR reaction is minimal, hence just double stranded DNA has 
enough quantity to be explored in PCR product. The read-out is showed by the number 
RI3&5F\FOHV OLNH F\FOH WKUHVKROG&W IRU VKRUW QHHG WR DFKLHYH WKH IOXRUHVFHQFH¶V
given level. During the original PCR cycles, fluorescence sent out by SYBR Green 
bound to PCR products, normally it is too ZHDNWRQRWH,QWKH3&5¶VH[SRQHQWLDOSKDVH
the fluorescence signal doubles at every cycle. A exact fluorescence signal doubling at 
every cycle is a main indicator of an appropriate assay. The fluorescent intensity 
usually trends to plateau means the PCR has attained saturation after more or less 32 
cycles. Since cycle threshold relates to the original quantity of target of sample, the 
correlative concentration of one target with respect to another is showed in the cycle 
QXPEHU¶VGLIIHUHQFHV ǻ&t = Ctsample ± CtreferenceQHHGWRUHDFKWKHVDPH IOXRUHVFHQFH¶V
level. There are many commercially SYBR Green chemistry kits can be used, like 
5RFKH¶V'1$PDVWHU6<%5® *UHHQ4LDJHQ¶V4XDQWL7HFK6<%5® Green PCR master 
PL[ %LRUDG¶V ,46<%5® Green supermix, MJ ResHDUFK¶V '\1$VLQ ,, '1$
polymerase with SYBR® Green and so on (Frederique, 2006). 
 
It is worth to note that once your experiment has been optimized by one 
chemistry, if you want to change chemistry kits, the re-optimization is necessary. 
Although the master mixes may be more expensive than individual reagents, in order to 
minimize the variability, the master mixes are recommended, or through using 
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homemade SYBR Green master mixes to decrease the cost (Karsai et al., 2002). 
 
1.5 Relationship with the prior experiment 
 
Growth promoter administration results in muscle fibre hypertrophy and changes 
in muscle fibre type composition, responses that are important in terms of human 
ageing and disease (such as sarcopenia and type 2 diabetes), as well as animal growth 
efficiency. 
 
As can be seen form the description above the produce of animals can be 
changed by the of utilization of growth promoters. Fundamentally the object is to 
change lean tissue production which will enable the more efficient production of the 
meat. This is important because of the limitations in the availability of food supplies for 
the world population. Also illustrated are the potential methodologies which will allow 
the dissection of this mechanisms by which these growth promoter agents work. 
Through the use of microarray it may be possible to identify these mechanisms which 
will allow manipulation of the growth process to enable more efficient production 
systems. 
 
On going research within the deviation of nutritional sciences has been 
examining the effects of growth promoter on sheep muscle growth..  
 
Specifically, a recent experiment has examined the effects on muscle physiology 
and target gene expression in response to short term (6 day) treatment of sheep (120 
days of age) with either beta-agonist (BA) and growth hormone(GH).  
 
The main finding of this study were (produced by Krystal Hemmings): 
 
1. Although just a short-term treatment with growth promoters, there has a trend for 
the weight of muscle to rise in response to beta-agonist in the 120 days of age 
lambs, however no influences were found with growth hormone.  
 
2. BA treatment significantly affected the metabolic activity in the longissimus dorsi 
(LD). The isocitrate dehydrogenase (ICDH) activity has been decreased, which 
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suggests a relational decrease in oxidative capacity, pointing metabolic transition 
towards a more glycolytic fibre type. This decrease also correlate with relevant 
varieties in signaling, involving an rise in the mRNA expression of the co-repressor 
receptor- interacting protein 140 (RIP140) and a decrease in the co-activator 
PGC-ȕ 
 
3. Although both growth promoters can lead a rise in muscle mass though different 
mechanisms, only BA has effects on fibre type composition of muscle. In other 
words, BA has strong effect on Myosin heavy chain mRNA expression in 
longissimus dorsi. 
 
In summary, the main finding of this study has been that the growth promoters, 
particularly BA, induced muscle growth and this appeared to be a switch to a muscle 
type that was a fast type with an apparent reduction on the oxidative metabolic 
capacity. 
 
As current available sheep microarrays are more targeted to study genes involved 
in immune response and not suitable for studies on muscle growth and metabolism. A 
human Affymetric arrary and genomic DNA hybridization were used to investigate 
effects of beta-agonist and growth hormone on the sheep muscle transcriptome (in 
collaboration with Sean May).  
 
   This microarrays dataset is available but in order to identify muscle growth 
signaling pathways specific or common to beta-agonist and growth hormone, the 
GeneSpring GX11 and Ingenuity Pathway Analysis software had been used to fully 
analyze the data. Identification of the microarray results was performed using real-time 
quantitative RT-PCR. 
 
1.6Hypothesis and Objectives 
 
The aim of the project was to further analyze and explain the results from Krystal 
Hemmings, which would enable a better understanding increase the animal growth 
efficiency. 
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Hypothesis: Growth promoter administration to sheep will lead to the effects on 
muscle gene expression which when detected by microarray analysis will indicate the 
specific pathways and target genes which mediate this response.  
 
Therefore the objectives of this project were 
1. To analyze the data produced from a microarray examination of the effects of 
growth promoters on sheep skeletal muscle. This will include: 
a. Identify up and down regulated genes and commonality and differences 
between the two growth promoters.  
b. Examination of potential interactions between genes whose expression 
had been altered to try to identify signaling pathways that are effected 
by the agents 
c. The identification gene expression alterations which are associated with 
specific pathways which maybe involved in mediating the response top 
the growth agents 
2. On selected genes associated with specific pathways that respond to the agents 
confirm changes in gene expression identified by microarray using quantitative 
RT-PCR 
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2 MATERIALS AND METHODS 
 
2.1Animal trial 
 
Male lambs were kept with their mothers until 53 ± 4 days of age then they were 
weaned and penned individually until 12o days of age (D120 age). Creep feed started 
about 28 days before weaning and lambs were given free access from weaning onwards. 
Before the three treatments, lambs were penned with ad- libitum access to creep feed for 
7 days. 
 
These D120 age lambs were separated into three treatment groups. The difference 
RI HDFK JURXS¶V PHDQ ERG\ ZHLJKWV ZDV QRW VLJQLILFDQW )LUVW JURXS FRQWURO JURXS
(n=11) were fed ad- libitum. Second group, growth hormone group (n=10) were fed 
ad-libitum and injected prolonged release bovine growth hormone (POSILAC®, 
Monsanto) on the first day. The dose was 3.75mg/kg BW. Third group, beta-agonists 
group (n=10) were fed ad- libitum and 10 ppm cimaterol (supplied by Pfizer Ltd). All of 
these treatments started at 120 ± 4 days of age and sustained six days.  
 
At slaughter, the samples from LD (from left side of sheep carcass at the 10th rib) 
were snap-frozen in liquid nitrogen then stored at 80 degrees below zero centigrade. All 
of the frozen LD muscles were dissected from the right side of the sheep carcass, 
crushed and mixed for next experiment (Supplied by Zoe Daniel).  
 
2.2 Cross-species microarray 
 
As current available sheep microarrays are more targeted to study genes involved 
in immune response and not suitable for studies on muscle growth and metabolism, and 
the aim of this project is to identify the growth signaling pathways in sheep skeletal 
muscle, therefore the human GeneChip array (Affymetrix-GeneChip Human Genome 
U133 Plus 2.0) was selected to hybridize with Sheep genomic DNA .  
 
   The RNA samples from sheep muscle were analyzed by NASC Xspecies technique 
(Hammond et al. 2005). The GeneChip operating system (GCOS; Affymetrix ), 
GeneSpring GX 11 (Agilent Technologies) and NASC Xspecies filter were used to 
analyze this cross-species microarray data, as described by Daniel et al (2008).  
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2.3 Bioinformatics 
 
2.3.1 Software analysis 
 
2.3.1.1 GeneSpring GX 11  
 
In this project, GeneSpring GX 11 (Agilent Technologies) was used to analyze the 
changes of gene expressions after three treatments (beta agonists, growth hormone and 
normal), how well does the sheep skeletal muscle on human microarray works and try 
to identify sheep muscle growth signaling pathways specific or common to beta 
agonists (BA) group and growth hormone (GH) group. The steps of GeneSpring GX 
11.0 analysis showed below. 
 
1) Loaded initial data and created experiments in GeneSpring GX 11.0.  By using 
RMA normalization algorithm to load the RNA files into GeneSpring GX 11.0 (Irizarry 
et al.,2003). This RNA files were analyzed by the .CDF files emerged from the 
genomic DNA hybridization, as described by Neil S. et al (2009). The probes with 
hybridization signal less than 450 in the genomic DNA hybridization had been 
removed. 
 
2) Profile plots analysis. Profile plots is an important visualizations that can cleanly 
display the change trend of gene expression against the fold change and different colors. 
In this project, the profile plots function was used to show the different expression and 
fold change of every gene in beta agonist treatment group, control group and growth 
hormone treatment group.  
 
3) Statistical analysis. Used one way analysis of variance (ANOVA) to test the initial 
data. Chose the genes which meet P value less than 0.05 (nDPHG³$IWHU$129$JHQH
JURXS´WRDQDO\]HLQQH[WVWHS  
 
4) Principal components analysis (PCA). It was used to view the separation of the 
sample groups of beta agonist (BA) treatment, control and growth hormone (GH) 
treatment. The quality of data was checked by this step. 
 
5) Gene ontology analysis (GO analysis). This module was used to explore gene 
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ontology and display the percent of the genes which have similar functions. The genes 
(from ³$IWHU$129$JHQHJURXS´) which met p value less than 0.05 had been 
explored.  
 
6) Filtered on volcano plot. Volcano plot can represent a visual summary of fold 
change value and p value. In this case, the corrected p-value cutoff was 0.05; the fold 
change cutoff was 1.5 (Fold change = Condition 1/Condition 2), T Test unpaired, 
asymptotic p-value computation, no multiple testing correction. The up and down 
regulated genes were found by this step.  
 
By comparing the gene expression of the treatment groups (BA and GH) with 
control group, four gene groups had been built. The fLUVWJURXSQDPHG³8S-regulated 
E\%$JURXS ´WKHJHQHVRIWKLVJURXSXS-regulated by beta-agonist (BA) relative to the 
FRQWUROJURXS7KHVHFRQGJURXSQDPHG³'RZQ-UHJXODWHGE\%$JURXS ´WKHJHQHVRI
this group down-regulated by beta-agonist (BA) relative to the control group. The third 
JURXSQDPHG³8S-UHJXODWHGE\*+JURXS ´WKHJHQHVRIWKLVJURXSXS-regulated by 
growth hormone (GH) relative to the control group. The fourth group named 
³'RZQ-UHJXODWHGE\*+JURXS ´WKHJHQHVRIWKLVJURXSGRZQ-regulated by growth 
hormone (GH) relative to the control group.  
 
   %\PHUJLQJ³8S-UHJXODWHGE\%$JURXS ´DQG³'RZQ-UHJXODWHGE\%$JURXS ´D
QHZJURXSKDGEHHQPDGHQDPHG³8SRUGRZQ-UHJXODWHGE\%$JURXS ´%\PHUJLQJ
³8S-UHJXODWHGE\*+JURXS ´DQG³'RZQ-regulated E\*+JURXS ´DQRWKHUQHZJURXS
KDGEHHQPDGHQDPHG³8SRUGRZQ-UHJXODWHGE\*+JURXS ´  
 
7) Venn diagram analysis. Venn diagram was used to capture the common and 
different genes between two of WKHJHQHJURXSVZKLFKIURP³)LOWHURQYROFDQRSORW ´
step. UsHGYHQQGLDJUDPIXQFWLRQWRFRPSDUH³8SRUGRZQ-UHJXODWHGE\%$JURXS ´
DQG³8SRUGRZQ-UHJXODWHGE\*+JURXS ´WKHFRPPRQJHQHVRIWKHPKDGEHHQIRXQG
and it will showed in )LJXUH7KLVFRPPRQJHQHJURXSQDPHG³FRPPRQJURXS´ 
 
8) Pathway analysis. The fRXUJHQHJURXSVZKLFK IURP³)LOWHURQYROFDQRSORW ´ VWHS
were mapped into the GeneSpring pathway database. This software integrated the 
information regarding dependencies of the genes and the dynamics in a new pathway. 
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GeneSpring had two different options of this pathway analysis step, Simple Analysis 
and Advanced Analysis. In this project, the Direct Interactions function of Simple 
Analysis had been used to find the direct relations between the target genes or proteins.  
 
9) Mapped into Kyoto Encyclopedia of Genes and Genomes (KEGG) database. In 
³SDWKZD\ DQDO\VLV ´ VWHS VRPH QHZ SDWKZD\V KDG EHHQ IRXQG ,Q RUGHU WR FRPSOHWH
these pathway results and research the biology process of them, the GeneSpring GX 
11.0 was used to map data in KEGG pathway database. This step of GeneSpring can 
supply a clearly visualization pathway that includes functional genes and biology 
process and it is useful for understanding and analyzing biology process and determine 
future experimental direction.  
 
2.3.1.2 Ingenuity Pathways Analysis 
 
IPA has eight kinds of analysis types, such as Core Analysis, IPA Metabolomics 
analysis, IPA Tox Analysis and IPA Biomarker Analysis. In this project, Core Analysis 
had been used. It allows users to interpret small or large datasets in the context of 
pathways, molecular networks and biological processes. The first step of IPA analysis 
was uploading data. ³8SRUGRZQ-UHJXODWHGE\%$JURXS ´ ³8SRUGRZQ-regulated by 
*+ JURXS ´ DQG ³FRPPRQ JURXS  ´ had been mapped in Ingenuity Pathway Analysis 
software (IPA version: 8.6-3003 Build: 93815;2010 Ingenuity Systems, Inc).  
Artificially changed different gene ID (Probe set ID, UniGene ID, GenBank and GI 
1XPEHUWKH³PDSSHG12XQPDSSHG12 ´RIWKUHHJHQHJURXSVZHUH³8SRU
down-UHJXODWHGE\ %$ JURXS´), 237/49 (³8SRU GRZQ-UHJXODWHGE\*+ JURXS´) and 
68/16 (³FRPPRQJURXS´). All of the unmapped genes had been checked, a vast majority 
of them referred to transcripts of unassigned function or were suspected to be 
ALU-repeat sequences, which were most unlikely to map anyway. This artificially 
PHWKRG FDQ PDS PXFK PRUH JHQHV WKDQ WKH ³,QJHQXLW\SDWKZD\ DQDO\VLV FRQQHFWRU´
function of Genespring and give researchers more opportunities to identify the 
SDWKZD\VWKH\KDYHQ¶WWKRXJKWRI  
 
The corn pathway functions of IPA, Networks Explorer and Canonical pathways, 
had been used in this project. The introductions of them showed below.  
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Networks Explorer. It is a useful function for visualizing molecular relationships. 
Genes, chemicals, and proteins are indicated as various shapes. In this project,³Up or 
down-regulated by GH group a´nd³common group´respectively produced 25 (Table 3.7) 
and 9 networks (Table 3.8). The analysis result of³Up or down-regulated by BA 
group´was composed of 25 networks (showed in Table 3.6), two of them respectively 
included v-akt murine thymoma viral oncogene homolog 1 (AKT1) and phosphoserine 
aminotransferase 1 (PSAT1). They were the core genes of the pathway result from 
GeneSpring. 
The Canonical Pathways Analysis. This step can dynamic and deeply display 
cell and metabolic signaling pathways which have been up-to-date and managed by 
Ph.D. level researchers. The renewed information and networks come from review 
articles, specific journal articles, textbooks and KEGG database. In this project, some 
important pathway results associated with oxidative metabolism and maybe involved in 
mediating the response of the growth agents had been found by the canonical pathway 
analysis. 
The flow chart and important gene groups of all software analysis process were 
showed by Figure 2.1 
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Figure 2.1 The summary chart of software analysis 
After loaded initial data in GeneSpring, used profile plots analys is to look at the expression and fold 
change of all gene. Then statistical analys is (one way ANOVA test ) had been used to find the 
VLJQLI LFDQWGDWDSYDOXHOHVVWKDQDQGWKHVHGDWDPDGHXSRI³$IWHU$129$JHQHJURXS´7KHQ
used PCA method to check the quality of samples. In the next step, GO analysis had been used to class 
 Profile plots analysis  
Initial data 
Statistical analysis.  
³$IWHU$129$JHQHJURXS´  
GO analysis  
Filter on volcano plot 
 
³8SRUGRZQ-UHJXODWHGE\%$JURXS´     ³8S-UHJXODWHGE\%$JURXS´ 
³8SRUGRZQ-regulated by GH JURXS ´     ³'RZQ-UHJXODWHGE\%$JURXS  ´  
                                           ³8S-UHJXODWHGE\*+JURXS  ´  
                                     ³'RZQ-UHJXODWHGE\*+JURXS´ 
                                           ³8SRUGRZQ-UHJXODWHGE\%$JURXS´ 
                                           ³8SRUGRZQ-UHJXODWHGE\*+JURXS´ 
Pathway analysis of 
GeneSpring, IPA and 
KEGG database 
Venn diagram analysis 
³FRPPRQJURXS´ 
Principal 
components 
analysis 
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the geQHV LQ³$IWHU$129$JHQHJURXS´DFFRUGLQJ WRELRORJ\ IXQFWLRQ7KHQ³$IWHU$129$JHQH
JURXS´ ZDV ILOWHUHG RQ YROFDQR SORW DQG VL[ LPSRUWDQW JHQH JURXSV KDG EHHQ EXLOW 7KHUH ZHUH
³8S-UHJXODWHG E\ %$ JURXS´ ³'RZQ-UHJXODWHG E\ %$ JURXS´ ³8S-regulated by GH JURXS´
³'RZQ-UHJXODWHGE\*+JURXS´³8SRUGRZQ-UHJXODWHGE\%$JURXS´DQG³8SRUGRZQ-regulated 
E\*+JURXS´$OORIWKHVL[JHQHJURXSVKDGEHHQDQDO\]HGE\9HQQGLDJUDPIXQFWLRQ7KHFRPPRQ
JHQHVRI³8SRUGRZQ-UHJXODWHGE\%$JURXS´DQG³8SRUGRZQ-UHJXODWHGE\*+JURXS ´EXLOW WKH
³FRPPRQ JURXS´ )LQDOO\ ³8S RU GRZQ-UHJXODWHG E\ %$ JURXS´ ³8S RU GRZQ-regulated by GH 
JURXS´DQG³FRPPRQJURXS ´KDGEHHQPDSSHGLQSDWKZD\DQDO\VLVIXQFWLRQRI*HQH6SULQJ,3$DQG
KEGG database to explore pathways. 
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2.3.2 Sequence search 
 
In this experiment, ovine DNA was hybridized to the human Affymetrix 
microarray in order to analyze sheep muscle gene expression. Therefore this project 
QHHGVUHVHDUFKHUWRVHDUFKRYLQH(67VVHTXHQFH LQVWHDGRI XVLQJWKHKXPDQ¶VVHTXHQFH  
from GeneSpring directly for primer design. The searched genes from AKT1 pathway 
(Figure 3.9), PSAT1 pathway (Figure 3.15) and citrate cycle pathway (Figure 3.17). 
The flow chart of searching process showed below (Figure 2.2). 
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Target genes were searched in NCBI database ( http://www.ncbi.nlm.nih.gov/).  
 
 
Status 1                    Had ovine cDNA sequence. 
ź 
Aligned different ovine mRNA sequences found by different people (Clustal 
W2) 
ź 
Used the same part to design primer.  
 
 
 
Status 2.     No ovine cDNA sequences but had bovine cDNA sequences.  
ź 
Aligned different bovine mRNA sequences found by different people (Clustal 
W2) 
ź 
Blasted the similar bovine CDS sequence in sheep ESTs database (www. 
ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=9940). Chose the 
result with highest score. (If the CDS number is not showed in NCBI, used 
KXPDQ¶V&'6WRGHILQHWKHERYLQH¶V 
ź 
Used Clustal W2 (www.ebi.ac.uk/Tools/clustalw2/index.html) and EMBOSS 
Pairwise Alignment Algorithms (www.ebi.ac.uk/Tools/emboss/align/index.html) 
to do alignment and checked the similarity between bovine mRNA and ovine 
EST sequences.  
ź 
 The ovine EST sequence had high similarity score (more than 75 or 18.0 percent) 
can be used to design primer. 
 
 
 
Status 3.   No ovine and bovine cDNA sequences but had human cDNA 
sequences. 
ź 
Aligned different human mRNA sequences found by different people (Clustal 
W2) 
ź 
Blasted the similar human CDS sequence in sheep ESTs database. Chose the 
result with highest score.                                   
(www.ncbi.nlm.nih.gov /genome/seq/BlastGen/BlastGen.cgi?Taxid =9940 ).  
ź 
Used ClustalW2 (www.ebi.ac.uk/Tools/clustalw2/index.html) and EMBOSS 
Pairwise Alignment Algorithms(www.ebi.ac.uk/Tools/emboss/align/index.html) 
to do alignment and checked the similarity between human mRNA and ovine 
EST sequences. 
ź 
The ovine ESTs sequence had high similarity score (more than 75 or 18.0 percent) 
can be used to design primer. 
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Figure 2.2 The flow chart of searching process 
 
2.4 Primer design 
 
After sequences searching, ovine EST sequences had been load into Cow BLAT 
Search online software (http://genome.ucsc.edu/cgi-bin/hgBlat) to find the exon 
boundaries for primer design. Designed primers used Primer Express 3.0 (Applied 
Biosystems) to suit real time PCR parameters. These parameters were shows below 
(Table 2.1) and the summary table of finally designed primers will show in Appendix 1. 
 
Table 2.1 Parameters of primer design 
Parameter  Value  
Primer Temperature  
Min Primer Temperature 58 
Max Primer Temperature 60 
Max Difference in Temperature of Two Primers  2 
Primer GC Content 
Mix Primer %GC Content 30 
Max Primer %GC Content 80 
Max Primer 3' GC's 2 
Primer 3'End Length 5 
Primer 3'GC Clamp Residues  0 
Primer Length 
Min Primer Length 9 
Max Primer Length 40 
Optimal Primer Length 20 
Primer Composition 
Max Primer G Residues  3 
Max Num Ambig Residues in Primer 0 
Primer Secondary Structure 
Max Primer Consec Base Pair 4 
Max Primer Total Base Pair 8 
Primer Site Uniquencess 
Max % Match in Primer 75 
Max % Consec Match in Primer 9 
Max % 3' Consec Match in Primer 7 
Amplicon 
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Min Amplified Region Temperature  0 
Max Amplified Region Temperature  85 
Min Amplified Region Length 50 
Max Amplified Region Length 150 
 
2.5 Quantitative real-time PCR 
 
Total RNA was isolated from all samples using Trizol as per manufacturers 
instructions including glycogen removal (Invitrogen,Paisley,UK) and an additional 
DNase step (Promega) and phenol/ chloroform/ isoamylalcohol clean up. The isolated 
total RNA was resuspended in RNase-free water and frozen at ±80°C until required. 
Yield and purity were determined using the Nanodrop DN-1000 (Thermo Scientific). 
(Supplied by Zoe Daniel) 
 
First Strand cDNA synthesis. Every reaction tube (thin walled 0.2ml PCR tube) 
added 5 ul total RNA stock (0.1ug/ul; 10pg-5ug total RNA), 1ul Random Primers 
(50-250ug random primers) and 9 ul water. Then put them in PCR machine, incubated 
70 degrees centigrade for 5 minutes and then put on ice for 1 minute. After that added 
5ul MMLV Reverse Transcriptase buff
water in each tube. The final volume was 25 uL. Mixed and spun down, then incubated 
at room temperature for 10 minutes and returned to the PCR machine for 42 degrees 
centigrade for 60 minutes and held at 4 degrees centigrade. This process as described 
by the manufacturer (Promega, Southampton, UK).  
 
Oligreen for determining cDNA quantity. Made 1x TE buffer by diluting 20 x TE 
buffer 1:20 in RNAse free water, then made working reagent of Oligreen cDNA reagent 
by diluting 1:200 in 1 x TE buffer. After this added 5uL working reagent and 5uL 
cDNA into one well of 384 well plate (Poche cat). Incubate plate in dark for 5 minutes 
and ran on Roche Light Cycler 480. The data from Light Cycler 480 was used to make 
standard curve to check the quantity of cDNA. 
 
Checked primer pairs(Sigma Alorich) on serial dilution of LD cDNA. Real-time 
PCR reactions using the primers described in Appendix 1. Ran samples and standard 
curve for 3 selected genes and cyclophillin. These genes were clathrin, light chain (Lca) 
 38 
(CLTA), forkhead box P1 (FOXP1) and rhomboid, veinlet- like 1 (RHBDL1). The real 
time PCR process was described below. 
 
Every well of 384 well plates (Poche cat) carried 7.5 uL 1x SYBR Green PCR 
Master Mix (Roche), 0.45 uL forward primer (0.3 uM), 0.45 uL reverse primer (0.3 
uM), 1.6 uL water (molecular grade), and 5 uL cDNA (1 in 4 or 1in 8 dilution). The 
final volume was 15 uL. Mixed and spun down by centrifuge for 5 minutes, and then 
read on Light Cycler 480 PCR machine (Roche): 95°C for 5 minutes, then 95°C For 10 
seconds, and then 45 cycles of 95°C for 1 second and 60°C for 20 seconds. The 
fluorescence was detected in real time and threshold CP values were calculated using 
LC480 software. Used melt curve analysis to make sure only giving one produce and 
that the standard curve was linear with an efficiency of less than 2. The data had been 
test by one way ANOVA test (Genstat 12th).  
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3 RESULTS  
 
3.1 Checking the quality of microarray data  
 
The result of this part mainly proved that the microarray data after one way 
analysis of variance test had good quality. 
 
The initial data had been loaded in GeneSpring, all of the raw data was cleanly 
displayed in profile plots (Figure 3.1). This figure showed the changes of expression of 
all the initial gene against the fold change and three different colors. After this step, 
used ANOVA to test the initial data, genes which meet P value less than 0.05 had been 
FKRVHWRPDNHXSRI³$IWHU$129$JHQHJURXS ´7KHFigure 3.2 showed the 
H[SUHVVLRQ¶VFKDQJHVRIJHQHVZKLFKPHHW3YDOXHOHVVWKDQ%\FRPSDULQJFigure 
3.1 and Figure 3.2, it is easy to see that the number of genes in Figure 3.2 is less than in 
Figure 3.1. This trended to prove that the ANOVA test worked.  
 
,Q WKH QH[W VWHS ³After ANOVA JHQH JURXS´ KDG EHHQ DQDO\]HG E\ Principle 
Component Analysis. In the result figure (Figure 3.3), the different treatment groups 
separated from each other and the replicates of each group clustered together in one 
side of three-dimensional photo. This demonstrated that the three sample groups had 
significant differences and the microarray data has good quality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.1 Profile plots of initial data  Figure 3.2 Profile plots of the data after 
one way ANOVA test (p value less than 
0.05). 
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In Figure 3.1 and Figure 3.2, X axis shows different treatments: beta agonist (BA), control (CK) and 
growth hormone (GH). Y axis displays the expression intensity value of genes. Red lines indicate 
the genes up-regulated by beta-agonist (BA) relative to the control group (CK), and the genes 
down-regulated by beta-agonist (BA) relative to the control group (CK) were colored by blue. 
Yellow lines means the genes have similar expression relative to the control group (CK). 
 
 
Figure 3.3 Principle Component Analysis (PCA) of the data after one way ANOVA 
test. 
Red color shows the triplicate samples that were treated by beta agonist, and the blue color shows 
the triplicate samples that were treated by growth hormone. Brown points display control samples.  
 
3.2 Grouping genes according to biology function  
 
The result of this part mainly indicated that the different groups of significant 
genes based on biology functions.  
 
Gene ontology analysis (GO analysis) was used to explore gene ontology and 
GLVSOD\HG WKHSHUFHQW RI WKH JHQHVZKLFK KDYH VLPLODU IXQFWLRQ ³$IWHU$129$ JHQH
JURXS ´ KDGEHHQXVHGWRDQDO\]HE\*2DQDO\VLV7KHUHZHUHWKUHHPDLQ IXQFWLRQVKDG
been found: molecular function, biological process and cellular component. Table 3.1 
showed the functional sub-groups of biological process. The functional sub-groups of 
cellular component was displayed in Table 3.2. Table 3.3 indicated the functional 
sub-groups of molecular function.  
 
³&RXQW ´ LQ *2DQDO\VLV WDEOHV 7DEOH 7DEOH DQG 7DEOH UHIHUV WR WKH
QXPEHU RI JHQHV ZKLFK KDYH VLPLODU JHQH RQWRORJ\ WHUP ³3HUFHQW ´ UHIHUV WR WKH
SHUFHQWDJHRIJHQHVZKLFKKDYHVLPLODUJHQHRQWRORJ\WHUPLQWKH³$IWHU$129$JHQH
JURXS ´ 
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Table 3.1 Gene ontology chart of biological process 
GO Term Count Percent(% ) 
GO:009987|GO:008151 celluar process 990 24.42 
GO:008152 metabolic process 623 15.37 
GO:0065007 bio logical regulation  615 15.17 
GO:0032502 developmental process 320 7.89 
GO:0032501|GO:0050874 multicelluar organis mal p rocess 316 7.79 
GO:0051179 localization  293 7.23 
GO:0051234 establishment of localization  256 6.31 
GO:0050896|GO:0051869 219 5.4 
GO:002376 immune system process 77 1.9 
GO:0022610 bio logical adhesion 69 1.7 
GO:0051704|GO:0051706 multi-organism process 61 1.5 
GO:00000003|GO:0019952|GO:0050876 reproduction  60 1.48 
GO:0043933|GO:0034600 macromolecular complex subunit 
organization  59 1.46 
GO:0022414 reproductive process 41 1.01 
GO:0040011 locomotion 26 0.64 
GO:0040007 growth  12 0.3 
GO:0048511 rhythmic process 8 0.2 
GO:0016032 viral reproduction 6 0.15 
GO:0043473 pigmentation 2 0.05 
GO:001906 cell killing  1 0.02 
 
Table 3.2 Gene ontology chart of cellular component 
GO Term Count Percent(% ) 
GO:0005623 cell 1210 28.39 
GO:0044464 cell part 1210 28.39 
GO:0043226 organelle  782 18.35 
GO:0044422 organelle part 393 9.22 
GO:0032991 macromolecular complex 219 5.14 
GO:0031974 membrane-enclosed lumen  145 3.4 
GO:0005576 ext racellular reg ion 128 3 
GO:0031975 envelope 71 1.67 
GO:0044421 ext racellular reg ion part 57 1.34 
GO:0045202 synapse 23 0.54 
GO:0044456 synapse part 14 0.33 
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GO:0044420 ext racellular matrix 8 0.19 
GO:0044423 virion part 1 0.02 
GO:0019012 virion 1 0.02 
 
Table 3.3 Gene ontology chart of molecular function 
GO Term Count Percent(% ) 
GO:0005488 binding  1061 50.55 
GO:0003824 catalytic activity  439 20.91 
GO:0060089 molecular transducer activity 188 8.96 
GO:0030528 transcription regulator activ ity 138 6.75 
GO:0005215|GO:0005478 transporter activity 100 4.76 
GO:0030234 enzyme regulator act ivity 73 3.48 
GO:0005198 structural molecu le activ ity 49 2.33 
GO:0045182 translation regulator activ ity 16 0.76 
GO:0009055|GO:0009053|GO:0009054 electron carrier activ ity  15 0.71 
GO:0016530 metallochaperone 3 0.14 
GO:0031386 protein tag 1 0.05 
GO:0016209 antioxidant activity 1 0.05 
GO:0015457 auxiliary transport protein activity 1 0.05 
 
3.3 Identification of target genes by Volcano plot 
 
The result of this part mainly identified the up and down regulated genes by 
comparing the treatment (BA and GH) data and control data.  
 
³$IWHU$129$JHQHJURXS ´ KDGWZR WUHDWPHQW JURXSV EHWDDJRQLVWDQGJURZWK
hormone) and control group. Used volcano plot to filter BA or GH group versus control 
group, the results showed in F LJXUHV  DQG )LJXUHV  7KHVH YROFDQR SORW¶V
corrected p-value cutoff were 0.05, fold change cutoff were 1.5. Used unpaired T Test 
to produced. Therefore, in Figures 3.4, there were 236 genes in the green pane of right 
side up-regulated by beta-agonist (BA) relative to the control group (p value < 0.05, 
fold change > 1.5 ), and 209 genes in the green pane of left side down-regulated by 
beta-agonist (BA) relative to the control group (p value < 0.05, fold change < -1.5 ). 
This result showed that BA had a clear effect on gene expression with approximately 
equal effects on increased and decreased expression. These up/down-regulated genes as 
the target genes for this project had been mapped in GeneSpring and IPA database to 
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identify pathways. The top 10 highest fold change genes of these up/down-regulated 
genes showed in Table 3.4. 
 
Similarly, in Figures 3.5, there were 147 genes in the green pane of right side 
up-regulated by growth hormone (GH) relative to the control group (p value < 0.05, 
fold change > 1.5 ), and 139 genes in the green pane of left side down-regulated by 
growth hormone (GH) relative to the control group (p value < 0.05, fold change < -1.5 ). 
This result also showed that GH had a clear effect on gene expression with 
approximately equal effects on increased and decreased expression. These 
up/down-regulated genes as the target genes for this project had been mapped in 
GeneSpring and IPA database to identify pathways. The top 10 highest fold change 
genes of these up/down-regulated genes showed in Table 3.5. 
 
There were 236 genes up-regulated by BA relative to the control group and 209 
genes down-regulated by BA relative to the control group, while there were 147 genes 
up-regulated by growth hormone (GH) relative to the control group, and 139 genes 
down-regulated by growth hormone (GH) relative to the control group. Hence, BA 
tended to change gene expression of more genes than GH.  
 
 
Figure 3.4 Volcano plot for the data treated by beta agonist (BA) versus the data treated 
by control. 
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The X axes shows the negative log10 of p-value and the Y axes displays the log (base2.0) of fold 
change. The red points in the green pane of right side indicate the genes satisfy p value less than 
0.05 and fold change more than 1.5. The red points in the green pane of left side indicate the genes 
satisfy p value less than 0.05 and fold change less than negative 1.5. The rest genes appear in gray 
color. 209 means the number of red points in left side and 236 means the number of red points in 
right side. The green lines means the cutoff of p-value is 0.05 and the cutoff of fold change is 1.5. 
 
Table 3.4. The top 10 highest fold change genes up-regulated by BA relative to control 
and top 10 highest fold change genes down-regulated by BA relative to control 
Probe set 
ID 
p-value Fold Change regulatio
n 
Gene 
symbol  
Gene ti tle 
206667_s_at 0.00124 6.5635695 up SCAMP1 secretory carrier membrane protein  
1 
44783_s_at 0.00423
8 
6.372318 up HEY1 hairy/enhancer-of-split related with 
YRPW motif 1 
209432_s_at 0.00792 5.2507415 up CREB3 cAMP responsive element binding 
protein 3 
1569871_at 0.00732
2 
4.411797 up LOC65039
2 
Hypothetical protein LOC650392 
201825_s_at 0.01170
7 
4.358996 up SCCPDH saccharopine dehydrogenase 
(putative) 
212857_x_a
t 
0.04597
1 
4.122034 up SUB1 SUB1 homolog (S. cerevisiae) 
234865_at 0.03611
9 
4.0604424 up TRBV25-1 T cell receptor beta variable 25-1 
205132_at 0.00581
3 
4.0215974 up ACTC1 actin, alpha, card iac muscle 1 
232006_at 0.00171
9 
3.2433836 up STK35 Serine/threonine kinase 35 
218140_x_a
t 
0.00188
4 
2.8869574 up SRPRB signal recognition particle receptor, 
B subunit 
204173_at 0.00086
1 
9.872075 down MYL6B myosin, light chain 6B, alkali, 
smooth muscle and non-muscle  
207318_s_at 0.00962
2 
5.3139696 down CDC2L5 cell d ivision cycle 2-like 5 
(cholinesterase-related cell d ivision 
controller) 
1552777_a_
at 
0.00927
3 
5.024218 down RAET1E retinoic acid early transcript 1E 
203543_s_at 0.02499
2 
3.6362588 down KLF9 Kruppel-like factor 9 
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213301_x_a
t 
0.00400
1 
3.5485144 down TRIM24 tripartite mot if-containing 24 
229060_at 0.03591
8 
3.5231614 down YPEL2 yippee-like 2 (Drosophila) 
228856_at 0.02667
6 
3.4488096 down ZNF747 zinc finger protein 747 
224357_s_at 0.04984 3.123486 down MS4A4A  membrane-spanning 4-domains, 
subfamily A, member 4 
223179_at 0.00317
6 
2.9623978 down YPEL3 yippee-like 3 (Drosophila) 
212977_at 0.02329
1 
2.9376898 down CXCR7 chemokine (C-X-C motif) receptor 
7 
 
 
Figure 3.5 Volcano plot for the data treated by growth hormone (GH) versus the data 
treated by control. 
The X axes shows the negative log10 of p-value and the Y axes displays the log (base2.0) of fold 
change. The red points in the green pane of right side indicate the genes satisfy p value less than 
0.05 and fold change more than 1.5. The red points in the green pane of left side indicate the genes 
satisfy p value less than 0.05 and fold change less than negative 1.5. The rest genes appear in gray 
color. 139 means the number of red points in left side and 147 means the number of red points in 
right side. The green lines means the cutoff of p-value is 0.05 and the cutoff of fold change is 1.5. 
 
Table 3.5 The top 10 highest fold change genes up-regulated by GH relative to control 
and top 10 highest fold change genes down-regulated by GH relative to control 
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Probe set ID p-value Fold 
Change 
regulation Gene 
symbol  
Gene ti tle 
204204_at 0.01009 3.6135406 up SLC31A2 solute carrier family 31 (copper 
transporters), member 2 
218387_s_at 0.00283 3.469396 up PGLS 6-phosphogluconolactonase 
201825_s_at 0.00788 3.3515317 up SCCPDH saccharopine dehydrogenase 
(putative) 
230464_at 0.0071 2.91482 up S1PR5 sphingosine-1-phosphate receptor 
5 
210691_s_at 0.00771 2.760892 up CACYBP calcyclin b inding protein 
1562411_at 0.00766 2.718481 up MYLK3 myosin light chain kinase 3 
217316_at 0.01627 2.631674 up OR7A10 olfactory receptor, family 7, 
subfamily A, member 10 
205509_at 0.0176 2.5984006 up CPB1 carboxypeptidase B1 (tissue) 
208790_s_at 0.00999 2.4406958 up PTRF polymerase I and transcript release 
factor 
1557987_at 0.00819 2.418115 up LOC641298 SMG1 homolog, 
phosphatidylinositol 
3-kinase-related kinase 
pseudogene 
1552777_a_at 0.01145 4.648777 down RAET1E retinoic acid early transcript 1E 
244684_at 0.01076 3.375558 down PGGT1B Protein geranylgeranyltransferase 
type I, beta subunit 
212924_s_at 0.02454 2.90002 down LSM4 LSM4 homo log, U6 s mall nuclear 
RNA associated (S. cerevisiae) 
218533_s_at 0.00454 2.749083 down UCKL1 uridine-cytid ine kinase 1-like 1 
220093_at 0.031 2.7295175 down ANTXR1 anthrax toxin receptor 1 
221580_s_at 0.00371 2.7195306 down TAF1D TATA box binding protein 
(TBP)-associated factor, RNA 
polymerase I, D, 41kDa  
202233_s_at 2.85E-04 2.5676868 down UQCRH ubiquinol-cytochrome c reductase 
hinge protein 
235252_at 0.02406 2.5175514 down KSR1 Kinase suppressor of ras 1 
202681_at 0.03915 2.5004194 down USP4 ubiquitin specific peptidase 4 
(proto-oncogene) 
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226465_s_at 0.0223 2.4167554 down SON SON DNA binding protein 
 
3.4 Exploring commonality and differences of gene expression between 
two growth promoters by Venn diagram 
 
The up and down regulated genes had been foXQG LQ ³)LOWHULQJRQYROFDQRSORW´
step, the results of this part mainly indicated that the common and different genes 
between the two growth promoters.  
 
From the results of volcano plot analysis, it was easy to see that there were a total 
of 445 (209 plus 236) genes up-regulated or down-regulated by BA relative to control 
(CK) and a total of 286 (139 plus 147) genes up-regulated or down-regulated by GH 
relative to control (CK). In Figure 3.6, there were 84 genes up-regulated or 
down-regulated by both treatPHQWV7KHVHJHQHVPDGHXSRI ³FRPPRQJURXS ´ WKDW
had been used to map in pathway analysis of GeneSpring and IPA database to identify 
pathways. In order to show the expression of genes more clearly, the Venn diagrams of 
up-regulated genes and down-regulated genes were displayed in Figure 3.7 and Figure 
3.8 respectively. 
 
³)LOWHURQYROFDQRSORWDQDO\VLV ´ VWHSVKRZHGWKDWWKHUHZHUHDWRWDORIJHQHV
up-regulated by BA relative to control (CK) and 147 genes up-regulated by GH relative 
to CK (Figure 3.7), with 39 genes up-regulated by both treatments. Similarly, there 
were a total of 209 genes down-regulated by BA relative to CK and 139 genes 
down-regulated by GH relative to CK (Figure 3.8), with 44 genes down-regulated by 
both treatments. Hence, BA tended to alter gene expression of more genes than GH.  
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Figure 3.6 Venn diagram of numbers of genes up-regulated or down-regulated by BA 
and/or GH relative to control (CK).  
The Red pie shows the numbers of genes up-regulated or down-regulated by beta-agonist (BA) 
relative to the control group (CK); while the blue pie shows the numbers of genes up-regulated or 
down-regulated by Growth Hormone (GH) relative to the control group (CK), with the intersect 
indicating the numbers of genes up-regulated or down-regulated by both BA and GH.  
 
 
 
 
 
 
 
 
 
Figure 3.7 Venn diagram of numbers of genes up-regulated by BA and/or GH relative 
to control (CK).  
The Red pie shows the numbers of genes up-regulated by beta-agonist (BA) relative to the control 
group (CK); while the blue pie shows the numbers of genes up-regulated by Growth Hormone (GH) 
relative to the control group (CK), with the intersect indicating the numbers of genes up-regulated 
by both BA and GH.  
 
 
 
 
 
 
 
 
 
Figure 3.8 Venn diagram of numbers of genes down-regulated by BA and/or GH 
relative to control (CK). 
The Red pie shows the numbers of genes down-regulated by beta-agonist (BA) relative to the 
control group (CK); while the blue pie shows the numbers of genes down-regulated by Growth 
Hormone (GH) relative to the control group (CK), with the intersect indicating the numbers of 
genes down-regulated by both BA and GH. 
 
3.5 Pathway analysis  
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3.5.1 All pathways identified by Ingenuity Pathways Analysis 
 
7KUHHJHQHJURXSVKDGEHHQPDSSHGLQ,3$³8SRUGRZQ-regulated by BA 
JURXS ´³8SRUGRZQ-UHJXODWHGE\*+JURXS´DQG³FRPPRQJURXS ´All of the IPA 
pathway results of each group had been showed in Table 3.6, Table 3.7 and Table 3.8. 
These tables included scores and the main functions of each network. The scores had 
been got by counting how many inputted gene can been mapped in the pathway. 
Compared Table 3.6 with Table 3.7, there were more networks which had high scores 
(more than 10) had been found in the group treated by BA than the group treated by 
GH. This trended to prove that BA had more predominantly effects to sheep skeletal 
muscle than GH. 
 
,QDOORIWKH ,3$QHWZRUNV LGHQWLILHG IRUP³8SRUGRZQ-UHJXODWHGE\%$JURXS ´
top NO.3 network (Figure 3.16) and top NO. 5 (Figure 3.12) network included PSAT1 
and AKT1 respectively, which were the core genes of PSAT1 pathway (Figure 3.15) 
and AKT1 pathway (Figure 3.9) generated by GeneSpring. In addition, the top number 
15 and top number 16 networks in Table 3.6 had direct relationship with skeletal 
development (colored by gray). 
 
Table 3.6 $OO,3$QHWZRUNVLGHQWLILHGIURP³8SRUGRZQ-UHJXODWHGE\%$JURXS´ 
The pathway had direct relationship with skeletal development had been colored by gray. 
Network 
NO. 
Score Top Functions of networks 
 1  41  Cardiovascular Disease, Ce llu lar Development, Connective Tissue Development 
and Function 
 2  30  Cancer, Respiratory Disease, Infection Mechanism 
 3  29  Cardiovascular System Development and Function, Cell Morphology, Cellular 
Movement 
 4  26  Cardiovascular Disease, Developmental Disorder, Cell Morphology 
 5  25  Genetic Disorder, Neurological Disease, Psychological Disorders 
 6  25  Cell Death, Cardiovascular System Development and Function, Organ 
Development 
 7  20  Cellular Development, Cellular Growth and Proliferation, Hemato logical System 
Development and Function 
 8  19  Hematological Disease, Cellu lar Assembly and Organizat ion, Protein 
Degradation 
 9  18  Cancer, Hair and Skin Development and Function, Organ Development  
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 10  17  Lipid Metabolis m, Nucleic Acid Metabolism, Small Molecule Biochemistry 
 11  17  Small Molecu le Biochemistry, Cell Cycle, Cellular Development  
 12  17  Cellular Growth and Proliferat ion, Lipid Metabolis m, Molecular Transport  
 13  15  Cell-To-Cell Signaling and Interaction, Hemato logical Sys tem Development and 
Function, Hypersensitivity Response 
 14  15  Antimicrobial Response, Inflammatory Response, Infection Mechanism 
 15  15  Neuro logical Disease, Skeletal and Muscular System Development and Function, 
Tissue Morphology 
 16  15  Genetic Disorder, Skeletal and Muscular Disorders, Cellu lar Assembly and 
Organization 
 17  13  Cellular Assembly and Organization, Cellu lar Development, Cellular Growth and 
Proliferation 
 18  12  Gastrointestinal Disease, Cancer, Reproductive System Disease 
 19  2  Gene Expression, Infection Mechanism, Cancer  
 20  2  Hematological System Development and Function, Hematopoiesis, Tissue 
Morphology 
 21  2  Cellular Development, Developmental Disorder, Genetic Disorder  
 22  2  Cellular Development, Reproductive System Development and Function 
 23  2  Cellular Assembly and Organization, Cellular Compromise, DNA Replicat ion, 
Recombination, and Repair 
 24  2  Developmental Disorder, Dental Disease, Genetic Disorder 
 25  2  Cardiovascular Disease, Genetic Disorder,  Cancer 
 
Table 3.7 $OO,3$QHWZRUNVLGHQWLILHGIRUP³8SRUGRZQ-UHJXODWHGE\*+JURXS´  
Network 
NO. 
Score Top Functions 
 1  45  Tumor Morphology, Tissue Morphology, Cancer 
 2  38  Small Molecule Biochemistry, Endocrine System Development and Function, 
Energy Production 
 3  26  Cell-mediated Immune Response, Cellular Assembly and Organization, 
Cellu lar Development 
 4  24  Genetic Disorder, Respiratory Disease, Cellu lar Function and Maintenance 
 5  18  Lipid Metabolis m, Small Molecule Biochemistry, Endocrine System 
Development and Function 
 6  18  Cellular Growth and Pro liferat ion, Drug Metabolism, Endocrine System 
Development and Function 
 7  16  Cell-To-Cell Signaling and Interaction, Nervous System Development and 
Function, Cellu lar Assembly and Organization 
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 8  16  Cell Death, Cell Morphology, Cellular Assembly and Organizat ion  
 9  16  Cellular Growth and Pro liferat ion, Connective Tissue Development and 
Function, Card iovascular System Development and Function  
 10  14  Cell-To-Cell Signaling  and Interaction, Embryonic Development, 
Hematological System Development and Function 
 11  13  Developmental Disorder, Renal and Uro logical Disease, Cellular Compromise 
 12  7  Immunological Disease, Respiratory Disease, Cancer 
 13  2  Hematological System Development and Function, Hematopoiesis, Tissue 
Morphology 
 14  2  Cell Cycle, Embryonic Development, Organis mal Development  
 15  2  Reproductive System Development and Function, Tissue Development, 
Reproductive System Disease 
 16  2  Unknown  
 17  2  Unknown 
 18  2  Cancer, Reproductive System Disease, Cellular Development  
 19  2  Unknown 
 20  2  Unknown 
 21  2  Cancer, Genetic Disorder, Respiratory Disease 
 22  2  Nervous System Development and Function, Tissue Development, Genetic 
Disorder 
 23  2  Genetic Disorder, Metabolic Disease, Small Molecule Biochemistry  
 24  2  Unknown 
 25  1  Cell-mediated Immune Response, Cellular Movement, Dermatological 
Diseases and Conditions 
 
Table 3.8 All IPA networks identified form ³FRPPRQJURXS´ 
NO. Score Top Functions 
 1  35  Small Molecule Biochemistry, Endocrine System Development and Function, 
Carbohydrate Metabolism 
 2  34  Cellular Function and Maintenance, Cell Cycle, Cellu lar Assembly and Organization  
 3  29  Cellular Compromise, Cell Morphology, Cell-To-Cell Signaling and Interaction 
 4  2  Gene Expression, Infection Mechanism, Cancer  
 5  2  Hematological System Development and Function, Hematopoiesis, Tissue 
Morphology 
 6  2  Cellular Assembly and Organizat ion, Cellular Compromise, DNA Replicatio n, 
Recombination, and Repair 
 7  2  Cancer, Reproductive System Disease, Cellular Development  
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3.5.2 Examining potential interactions between the up and down 
regulated genes by GeneSpring  
 
There were many pathways had been found by GeneSpring. Two of them have been 
considered as key pathways to do further analysis. The key pathways will be showed 
below. 
 
3.5.2.1 AKT1 pathway 
 
0DSSHG ³8SRU GRZQ-UHJXODWHGE\ %$ JURXS´ LQ *HQH6SULQJ WR explore direct 
interactions between each target gene, the AKT1 pathway (Figure 3.9) which included 
most interactions had been found.  
 
AKT1 (V-akt murine thymoma viral oncogene homolog 1) down-regulated by BA 
relative to the control. It was the core of this pathway and there were 26 genes had 
direct or indirect relation with it. As recent research indicated that the AKT1or 
Atrogin-1(MAFbx)/MuRF1 signaling network is an vital route to the hypertrophy and 
differentiation of skeletal muscle (Coolican et al., 1997; Jiang et al., 1998; Glass, 2003; 
Nader. 2005; Chang 2007). Hence, this pathway was an important result of this project. 
And in the further work, qReal-Time PCR can be used to confirm the expression of 
these genes. 
 
:KHQ WKH ³8SRUGRZQ-UHJXODWHGE\%$JURXS ´ KDGEHHQPDSSHG LQ,3$$.7
also showed in the top number 5 network of all the IPA pathways. This network had 
EHHQ QDPHG ³$.7 QHWZRUN IURP ,3$´ )LJXUH  7KH PDLQ IXQFWLRQV RI WKLV
network was about Genetic Disorder, Neurological Disease and Psychological 
Disorders (showed in Table 3.6). This result proved the presence of AKT1 pathway and 
provided more information of it. Compared AKT1 pathway from GeneSpring with 
AKT1 network from IPA, there were much more genes linked to AKT1 in 
*HQH6SULQJ¶V UHVXOW WKHUHE\ *HQH6SULQJ ZDVEHWWHU WR ILQG WKH UHODWLRQVKLSVEHWZHH n 
each target gene than IPA. 
 
6LPLODUO\PDSSHG³8SRUGRZQ-UHJXODWHGE\*+JURXS ´LQ*HQH6SULQJWRexplore 
direct interactions between each target gene, Figure 3.14 had been found. From this 
figure it was easy to see that the number of genes in Figure 3.9 was much more than the 
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number of genes in Figure 3.14 when used the same method to explore the pathway. 
This trended to prove that beta-agonist had stronger effect to skeletal muscle than 
growth hormone. 
 
Figure 3.9 AKT1 pathway generated from GeneSpring analysis 
The red ellipses indicate the genes up-regulated by beta-agonist (BA) relative to the control group, 
blue ellipses indicate the genes down-regulated by beta-agonist (BA) relative to the control group. 
The gene with blue ring means this gene is in ³8SRUGRZQ-UHJXODWHGE\%$JURXS´. The gene does 
not have blue ring and was showed pink color, this means it is in the GeneSpring database and has 
relationship with this pathway, but not in the ³8SRUGRZQ-UHJXODWHGE\%$JURXS´, therefore it is 
not up or down regulated gene and colored by pink. Sometimes, one gene has to via more than one 
probe sets to express, however GeneSpring cannot map more than one probe sets in one ellipse, as a 
result this kinds of gene has blue ring but colored by pink. For example, FOXO3 and PRR5. There 
are up-regulated genes in this pathway. The lines between each ellipse show different biology 
relationship and processes, these were described in Figure 3.10 and Figure 3.11.  
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Figure 3.10 Edges legend of 
GeneSpring pathway analysis  
Figure 3.11 Relations legend of 
GeneSpring pathway analysis 
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Figure 3.12 AKT1 network generated from IPA 
Red shows the gene or protein up-regulated by beta-agonist (BA) relative to the control group, 
green shows the gene or protein down-regulated by beta-agonist (BA) relative to the control group. 
:KLWH PHDQV WKH PROHFXOH LV QRW LQ ³8S RU down-UHJXODWHG E\ %$ JURXS´ LW ZDV DGGHG IURP
Ingenuity Knowledge Base. AKT1 and its relationship lines were colored by blue. Blue dashed 
lines show indirect interactions and the blue solid lines display direct interactions. The meaning of 
various shapes were indicated in Figure 3.13. Different kinds of arrows and lines indicate the 
directionality of the interaction and specific molecular relationships, the details of them are 
showed in Figure 3.13. This network was displayed in Toggle Subcellular Layout (mapped 
PROHFXOHV¶VSDWLDO ORFDWLRQLQWRWKHLUUHOHYDQWVXEFHOOXODU ORFDWLRQV 
 
 
Figure 3.13 The legend of IPA network shapes and relationship types  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14  GH-direct interactions pathway generated from ³8SRUGRZQ-regulated 
by GH group´ 
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This figure shows the pathway in cellular layout. According to the information from the cellular  
component of Gene Ontology, genes have been located in the correlative cellular parts. Top yellow 
and middle blue parts respectively means plasma membrane and cytoplasm, while nucleus was 
displayed by bottom green part. The red ellipses in this figure indicate the genes up-regulated by 
growth hormone relative to the control group, blue ellipses indicate the genes down-regulated by 
growth hoUPRQH  UHODWLYHWRWKHFRQWUROJURXS7KHJHQHZLWKEOXHULQJPHDQVWKLVJHQHLVLQ³8S
or down-UHJXODWHG E\ *+ JURXS´ 7KH OLQHV EHWZHHQ HDFK HOOLSVH VKRZ GLIIHUHQW ELRORJ\
relationship and processes, these were described in Figure 3.10 and Figure 3.11.  
 
3.5.2.2 PSAT1 pathway 
 
0DSSHG ³8SRU GRZQ-UHJXODWHGE\ %$ JURXS ´ LQ*HQH6SULQJ WR H[SORUHGLUHFW
interactions, the PSAT1 pathway (Figure 3.15) had been found. PSAT1 (Phospho 
Serine Amino Transferase 1) was associated with synthesis of serine and showed 
up-regulated by BA relative to the control. There were some studies proved that PSAT 
over expression in cells in culture was associated with growth and cell proliferation 
(Baek. et.al 2003; Vie. et.al. 2008). 
 
   :KHQWKH ³8SRUGRZQ-UHJXODWHGE\%$JURXS ´ Kad been mapped in IPA, PSAT1 
DOVR VKRZHG LQ WKH WRS QXPEHU QHWZRUN 7KLV QHWZRUN KDGEHHQ QDPHG ³36$7
QHWZRUN IURP ,3$ ´ )LJXUH  7KH PDLQ IXQFWLRQV RI WKLV QHWZRUN ZHUH DERXW
Cardiovascular System Development and Function, Cell Morphology and Cellular 
Movement (showed in Table 3.6). Compared PSAT1 network from GeneSpring with 
PSAT1 network from IPA, there were more gene related to PSAT1 in PSAT1 network 
from GeneSpring, also proved that the GeneSpring was good at finding the 
relationship between target genes than IPA. 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 PSAT1 pathway generated from GeneSpring analysis 
The red ellipses in this figure indicate the genes up-regulated by beta-agonist (BA) relative to the 
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control group, blue ellipses indicate the genes down-regulated by beta-agonist (BA) relative to the 
FRQWUROJURXS7KHJHQHZLWKEOXHULQJPHDQVWKLVJHQHLVLQ³8SRUGRZQ-UHJXODWHGE\%$JURXS´ 
The lines between each ellipse show different biology relationship and processes, these were 
described in Figure 3.10 and Figure 3.11.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 PSAT1 network generated from IPA 
Red shows the gene or protein up-regulated by beta-agonist (BA) relative to the control group, 
green shows the gene or protein down-regulated by beta-agonist (BA) relative to the control group. 
:KLWH PHDQV WKH PROHFXOH LV QRW LQ ³8S RU GRZQ-UHJXODWHG E\ %$ JURXS´ LW ZDV DGGHG IURP
Ingenuity Knowledge Base. PSAT1 and its relationship lines were colored by blue. Blue dashed 
lines show indirect interactions and the blue solid lines display direct interactions. The meaning of 
various shapes were indicated in Figure 3.13. Different kinds of arrows and lines indicate the 
directionality of the interaction and specific molecular relationships, the details of them is showed 
LQ )LJXUH  7KLV QHWZRUNZDV GLVSOD\HG LQ 7RJJOH 6XEFHOOXODU /D\RXW 0DSSHG PROHFXOHV¶
spatial location into their relevant subcellular locations). 
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3.5.3 Specific pathways which maybe involved in mediating the 
response of the growth agents 
 
3.5.3.1 IPA Canonical pathway-citrate cycle pathway 
 
0DSSHG ³8SRU GRZQ-UHJXODWHGE\ %$ JURXS ´ LQ ,3$ WKH&LWUDWH&\FOH 7&$
cycle) pathway (Figure 3.17) as the top one significant Canonical pathway had been 
found. Its P value was 2.32E-04 and the ratio of IPA was 5/58 (0.086). The rank 
accorded to the number of IPA ratio. The calculated method of IPA ratio was: 
PROHFXOHV¶QXPEHULQDJLYHQSDWKZD\WKDWPHHWFXWRIIFULWHULDGLYLGHGE\WRWDOQXPEHU
of molecules that make up that pathway (www.ingenuity.com).  
 
In this pathway, five genes showed down-regulated and one gene showed 
up-regulated by BA. Therefore, these genes maybe decreased the biology function of 
TCA cycle. In other words, this figure suggested that action of beta-agonists trended to 
repress the citrate cycle to make more carbon. 
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Figure 3.17 IPA Canonical pathway-citrate cycle pathway 
Red shows the gene or protein up-regulated by beta-agonist (BA) relative to the control group, 
green shows the gene or protein down-regulated by beta-agonist (BA) relative to the control group. 
:KLWH PHDQV WKH PROHFXOH LV QRW LQ ³8S RU GRZQ-UHJXODWHG E\ %$ JURXS´ LW ZDV DGGHG IURP
Ingenuity Knowledge Base. The meaning of various shapes were indicated in Figure 3.13. 
Different kinds of arrows and lines indicate the directionality of the interaction and specific 
molecular relationships, the details of them is showed in Figure 3.13. The meaning of important  
symbols are showed in Table 3.9. The names of all symbols will display in Appendix 4. 
 
Table 3.9 The meanings of important symbols in citrate cycle pathway 
Symbol  Meaning 
1.1.1.42 isocitrate (NADP) dehydrogenase,  
1.3.5.1 complex II, fumarate reductase complex, menaquinol:fumarate oxidoreductase,  
1.3.99.1 Complex II, Succinate INT Dehydrogenase 
2.3.1.61 dihydrolipoamide succinyltransferase,  
2.3.3.8 acetyl-CoA:oxaloacetate acetyltransferase (isomerizing, ADP-phosphorylating),  
4.1.3.6 citratase, citrate aldolase, citrate oxaloacetate-lyase,  
 
3.5.3.2 IPA Canonical pathway-Oxidative Phosphorylation pathway 
 
0DSSHG ³8S RU GRZQ-UHJXODWHG E\ %$ JURXS ´ LQ ,3$ WKH 2[LGDWLYH
Phosphorylation pathway (Figure 3.18) had been found.  
 
This photo indicated that five genes down-regulated but only one gene 
up-regulated by BA. Therefore, these genes trended to decrease the whole process of 
oxidative phosphorylation associated with energy metabolism. In other words, this 
pathway suggested that action of beta-agonists tended to repress the electron transport 
chain to produce ATP. 
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Figure 3.18 IPA Canonical pathway- Oxidative Phosphorylation  
Red shows the gene or protein up-regulated by beta-agonist (BA) relative to the control group, 
green shows the gene or protein down-regulated by beta-agonist (BA) relative to the control group. 
White means the molecule is not in ³8SRUGRZQ-UHJXODWHGE\%$JURXS´ it was added from 
Ingenuity Knowledge Base. The meaning of various shapes were indicated in Figure 3.13. 
Different kinds of arrows and lines indicate the directionality of the interaction and specific 
molecular relationships, the details of them is showed in Figure 3.13. The meaning of important 
symbols are showed in Table 3.10. The names of all symbols will display in Appendix 5. 
 
Table 3.10 The meanings of important symbols in oxidativephosphorylation pathway 
Symbol  Synonym(s) 
1.10.2.2 coenzyme Q-cytochrome c reductase, coenzyme QH2-cytochrome c reductase,  
1.3.5.1 complex II, fumarate reductase complex, menaquinol:fumarate oxidoreductase,  
1.3.99.1 Complex II, Succinate INT Dehydrogenase 
1.6.5.3 complex 1 dehydrogenase, complex I (electron transport chain),  
1.6.99.3 beta-NADH dehydrogenase dinucleotide, cytochrome c reductase,  
3.6.3.14 ATP phosphohydrolase (H+-transporting), ATP synthase,  
 
3.5.3.3 Glycolysis network generated form KEGG database 
 
Used GeneSpring to map ³8SRU GRZQ-UHJXODWHGE\ %$ JURXS´ into KEGG 
pathway database. Through this analysis several pathways were identified which had 
JHQHZKR¶VH[SUHVVLRQZDVDIIHFWHG$V LQGLFDWHG LQ)LJXUH DSDWKZD\WKDW KDG
several genes influenced by BA treatment was glycolysis.  
 
This glycolysis is responsible for anaerobic respiration the product of the 
pathway is pyruvate which can reduced to lactic acid, as is the case in anaerobic 
respiration, or can be converted to Acetyl CoA and then this enters the TCA cycle and 
associated with energy metabolism. It also showed the PSAT and enolase were 
up-regulated by BA using Q-PCR (Tim Parr unpublished observations). PSAT is part 
of a pathway which utilizes intermediates of glycolysis to synthesize the non-essential 
amino acid serine whilst enolase is a enzyme which is part of glycolysis. As indicated 
in the Figure 3.19 and Table 3.11 the other enzymes within glycolysis that were 
affected were Fructose 1,6-bisphosphatase, Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and Phosphoglycerate mustase. Of these Fructose 
1,6-bisphosphatase is of particular interest as it is involved in promoting the reverse of 
JO\FRO\VLV3KRVSKRIUXFWRNLQDVHEHLQJLQYROYHGLQWKHPRYHPHQWRIVXEVWUDWHV³GRZQ´
glycolysis whilst Fructose 1,6-ELVSKRVSKDWDVH LV LQYROYHG LQ PRYLQJ VXEVWUDWHV ³XS´
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glycolysis. Therefore this step is a key regulatory step in the control of substrate flux 
through glycolysis. 
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Figure 3.19 Glycolysis network generated from GeneSpring 
1 
2 
3 
4 
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Yellow shows the gene or protein up-regulated by beta-agonist (BA) relative to the control group, 
green shows the gene or protein down-regulated by beta-agonist (BA) relative to the control group. 
White means the molecule is not in ³8SRUGRZQ-regulated E\%$JURXS´ it was added from 
KEGG database. The meaning of main symbols is showed in Table.3.11. 
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Table 3.11 The meaning of main symbols in Glycolysis pathway 
Symbol  name 
4.1.2.13 fructose-bisphosphate aldolase; fructose-1,6-bisphosphate triosephosphate-lyase; diphosphofructose aldolase; 
2.7.1.11 6-phosphofructokinase;phosphohexokinase;phosphofructokinase I; phosphofructokinase(phosphorylating);6-phosphofructose 1-kinase; 
5.3.1.9 glucose-6-phosphate isomerase;phosphohexose isomerase; hexosephosphate isomerase;phosphosaccharomutase; glucose phosphate isomerase; 
5.4.2.4 bisphosphoglycerate mutase; glycerate phosphomutase;bisphosphoglycerate synthase;bisphosphoglyceromutase; 2,3-diphosphoglycerate mutase;  
3.6.1.7 acylphosphatase;acetylphosphatase;1,3-diphosphoglycerate phosphatase;acetic phosphatase;Ho 1-3;GP 1-3 
3.1.3.13 bisphosphoglycerate phosphatase;2,3-diphosphoglycerate phosphatase;diphosphoglycerate phosphatase; 
5.4.2.1 phosphoglycerate mutase;phosphoglycerate phosphomutase;phosphoglyceromutase; 
5.4.2.2 phosphoglucomutase;glucose phosphomutase;phosphoglucose mutase 
2.7.1.40 pyruvate kinase;phosphoenolpyruvate kinase;phosphoenol transphosphorylase 
1 Fructose 1,6-b isphosphatase 
2 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
3 Phosphoglycerate mustase 
4 Enolase 
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3.5.4 Real-time PCR 
 
3.5.4.1 Sequences searching and primer design results 
 
According as the flow chart of searching process showed above (Figure 2.2), the 
sequences of main target genes from AKT1 pathway, PSAT1 pathway and citrate 
cycle pathway had been searched.  
 
As less ovine cDNA sequences had been found, therefore most of the genes used 
similar bovine cDNA for primer design. If some gene no ovine and bovine sequence, 
the similar human cDNA had been used for primer design (showed in Table 3.12). 
 
The CLUSTAL score and the number of EMBOSS Similarity indicated the 
similarity of bovine cDNA/human cDNA compared with Ovine EST sequence. These 
scores and numbers were showed in Table 3.13 and Table 3.14. By comparing the 
CLUSTAL score and the number of EMBOSS Similarity in Table 3.13 and Table 3.14, 
it is easy to see that the similarity of ovine versus bovine was higher than the 
similarity of ovine versus human, this suggested that ovine and bovine had higher 
homology than ovine and human. 
 
Table 3.12 Sequences summary for primer design 
,Q WKLV WDEOH³<(6´PHDQV WKHJHQHKDV+XPDQF'1$%RYLQHF'1$2YLQHF'1$2YLQH(67 
RUWKHF'1$(67FDQEHXVHGIRUSULPHUGHVLJQ³12´PHDQVWKHJHQHQR+XPDQF'1$%RYLQH
cDNA/Ovine cDNA/Ovine EST . 
Gene name Human 
cDNA 
Bovine cDNA Ovine cDNA Ovine ES T Use for 
primer 
design 
FOXP1 YES YES NO YES YES 
CLTA  YES YES NO YES YES 
RHBDL1 YES YES NO YES YES 
CD44 YES YES NO YES YES 
CXCR7 YES YES NO YES YES 
FOXO3 YES YES NO YES YES 
SUB1 YES YES NO YES YES 
ANK1 YES YES NO YES YES 
TIAM1 YES YES NO YES YES 
IFI44 YES YES NO YES YES 
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AKT1 YES YES YES --- YES 
 
TUBA1B YES NO NO YES YES 
C11orf17 YES NO NO YES YES 
CYP2C9 YES NO NO YES YES 
 
CLYBL YES YES NO YES YES 
DLST YES YES NO YES YES 
 
Table 3.13 The similarity of bovine cDNA and ovine EST 
Gene name Bovine cDNA (1) 
Full length  
Length              Bp 
Ovine ES T 
(length: Bp) 
(2) 
CLUSTAL 
score 
(1 and 2) 
EMBOSS 
Similarity (1 
and 2) 
FOXP1 YES 3309 682 97 666/3312 
(20.1%) 
CLTA  YES 1110 874 87 787/1176 
(66.9%) 
RHBDL1 YES 2309 499 96 483/2309 
(20.9%) 
CD44 YES 1355 540 94 510/1365 
(37.4%) 
CXCR7 YES 1745 841 96 810/1746 
(46.4%) 
FOXO3 YES 2050 376 98 370/2050 
(18.0%) 
SUB1 YES 3384 728 90 679/3384 
(20.1%) 
ANK1 YES 1750 795 85 682/1844 
(37.0%) 
TIAM1 YES 2821 661 97 646/2821 
(22.9%) 
IFI44 YES 1959 826 91 753/1986 
(37.9%) 
 
CLYBL YES 1046 641 66 563/1047 
(53.8%) 
DLST YES 2221 895 96 872/2221 
(39.3%) 
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Table 3.14 The similarity of human cDNA and ovine EST 
Gene name Human cDNA (1) 
Full length  
Length                Bp 
Ovine ES T 
(length: Bp) 
(2) 
CLUSTAL 
score 
(1 and 2) 
EMBOSS 
Similarity (1 
and 2) 
TUBA1B YES 1356 577 81 473/1436 
(32.9%) 
C11orf17 YES 1427 876 75 719/1438 
(50.0%) 
CYP2C9 YES 1273 493 76 381/1274 
(29.9%) 
 
3.5.4.2 PSAT1 pathway confirmed by qReal-time PCR 
 
The every target gene of PSAT1 pathway had been confirmed by qReal-time PCR. 
The qReal-time PCR result of PSAT1 showed high significant (p value less than 0.01, 
supplied by Zoe Daniel), the other three genes which had direct relationship with 
PSAT1 hadbeen checked by qReal-time PCR experiment. The results of CLTA 
( p-value = 0.026) and FOXP1( p-value = 0.009) were significant (Figure 3.20). These 
proved that the PSAT1 indeed up-regulated by BA, CLTA and FOXP1 really 
down-regulated by BA. This real- time PCR result was agree with microarray data.  
 
In the PSAT1 pathway, 3 of 4 genes had been confirmed. Only REBDL1 had not 
significant result, this may because microarray was too sensitive and actually REBDL1 
was not up-regulated by BA. However, since in this experiment the human array had 
been used to hybridize sheep sample to get this pathway result and the bovine cDNA of 
REBDL1 had been used to primer design, these effects also worth to be considered.  
 71 
 
Figure 3.20 Effects of BA and GH on LD muscle gene expression (targets relating to 
PSAT1 pathway) (supplied by Zoe Daniel). 
The X axes means there were four genes (REBDL1, CLTA, FOXP1 and PSAT1) and cyclophillin 
had been used to do qReal-time PCR. Y axes shows the number of target RNA expression is 
divided by the number of cyclophillin expression or total cDNA expression (only for PSAT1). 
Blue displays the qReal-time PCR result form the samples which treated by beta-agonist (BA). 
Red displays the qReal-time PCR result form the control samples (C). Green displays the 
qReal-time PCR result form the samples which treated by growth hormone (GH). The number of 
p-value is showed in the red boxes. 
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4 DISCUSSION 
 
In this investigation the following hypothesis was investigated.  
 
Hypothesis of this study: Growth promoter administration to sheep will lead to 
the effects on muscle gene expression which when detected by microarray analysis 
will indicate the specific pathways and target genes which mediate this response.  
 
From the examination of the data there were some target genes and pathways had 
been identified, these included AKT1 pathway (Figure 3.9) and PSAT1 pathway 
(Figure 3.15) associated with protein synthesis, and citrate cycle pathway (Figure 
3.17), oxidative phosphorylation pathway (Figure 3.18) and glycolysis network 
(Figure 3.19) correlated with energy metabolism. These pathways were predominantly 
associated with beta-agonists response in comparison there were only relatively minor 
effects of growth hormone .  
 
As indicated in the introduction specific objectives were investigated. Indicated 
below are those objectives and the principal outcomes which were determined.  
 
1. To analyze the data produced from a  microa rray examination of the effects of 
growth promoters on sheep skeletal muscle. This will include:  
a.  Identify up and down regulated genes and commonality and differences 
between the two growth promoters. 
8VHG WKH ³)LOWHULQJRQ YROFDQRSORW ´ DQG ³9HQQGLDJUDP´ IXQFWLRQVRI
GeneSpring, the up and down regulated genes and the intersections of them 
have been found. In the analysis of the microarray there was a clear effect on 
gene expression with approximately equal effects on increased and decreased 
expression. However it was noticeable that more genes were affected in the 
beta-agonists treated. 
 
b. Examination of potential interactions between genes whose expression had 
been altered to try to identify signaling pathways that are effected by the 
agents. 
Used pathway analysis of GeneSpring and IPA software, there were 
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several pathways had been identified. By comparing the identified pathways 
which effected by BA with GH, again indicated that the effects of BA were 
VWURQJHU WKDQ*+¶V)RFXVHGRQWKHSDWKZD\VZKLFKZHUHHIIHFWHGE\%$DQG
through examination of the literature, two predominant pathways had been 
identified. One was AKT1 pathway had the most associate/interactions, 
another one was PSAT1 pathway. It included PSAT which associated with the 
synthesis of serine. 
 
c. The identification gene expression alterations which a re associated with 
specific pathways which maybe involved in mediating the response of the 
growth agents 
Further analysis was carried out using pathway based program IPA and 
GeneSpring which allowed identification of the predominant pathways 
influenced by the agents. The most clear and significant observation was that 
there were a group of genes affected that were associated with oxidative 
metabolism. This included the TCA cycle, the electron transport chain found in 
mitochondria (Oxidative Phosphorylation pathway) and glycolysis network. 
 
2  On selected genes associated with specific pathways that respond to the agents 
confirm changes in gene expression identified by microarray using quantitative Real 
Time PCR 
One special group of genes associated with the serine synthesis pathway 
(PSAT1 pathway) was analyzed. From this analysis were able to confirm the 
changes observed by the microarray. Thereby placing a high level of confidence 
that the expression of genes associated with serine synthesis are affected by 
beta-agonists indicating that serine synthesis may be increased in this treatment.  
 
In today's world, to increase feed conversion efficiency (FCE) is very popular 
and welcomed by producers, consumers and environmentalists. Because it decreases 
production costs, while increase product quality and profit for producers. It also can 
provide meat to more people under the conditions of limited resources. And the other 
benefits are reduced grazing pressure and decreased nitrogenous excretion into the 
environment. Improvements in the ratio of lean to fat deposition or increases in FCE 
can be achieved by using some growth promoters, like beta-agonist (BA) and growth 
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hormone (GH). These growth promoters can increase muscle mass by rising fibre 
number and/or fibre size. We already know that IGF can activate PI3K-Akt1 pathway 
mediating this effect (Chang. 2007). But we still need to know more in order to 
identify potential targets for manipulation.  
 
It was clear that pathways which under the beta-agonists treatment were affected 
significantly than GH, and BA can influence muscle growth and switch fibre type 
(Enright, 1989; Buttery and Dawson, 1990). Myosin changes and potential AKT1 
changes that are associated with growth (Nader, 2005). Some indications of these 
changes can be found from this microarray data. As AKT1 can cause changes in 
protein synthesis. But in the AKT1 pathway of this project, AKT1 goes down. This is 
puzzling. But we know that predominant regulation of AKT is at post-translational 
level with the control of the activity of this enzyme being through its phosphorylation.  
This post-translational modification activates the enzyme thereby leading to increased 
activation of downstream proteins in this signaling pathway which is associated with 
increases in protein synthesis. What needs to be done is to look at all the other genes 
associated which we found in the analysis to see if the changes seen are associated 
with a protein synthesis down or up regulation. Also do experiments to conform by 
Real-time PCR. In this project we used sheep sample to hybridize with human array to 
get this pathway result and most target genes used bovine or human cDNA to design 
primers, these reasons may effect the accuracy of Real-time PCR. However when we 
looked at PSAT pathway by Real-time PCR, it clearly indicated that this approach of 
cross-species array worked as the data confirmed the microarray data. PSAT 
associated with synthesis of serine. Serine is an amino acid so would be expected to 
be require in growth. Indeed data on PSAT shows that over expression in cells in 
culture is associated with growth and cell proliferation (Baek. et.al 2003; Vie. et.al. 
2008). Interestingly to note that the substartes which are used for the synthesis of 
serine originate from glycolysis.  
 
Another major outcome from pathway analysis was that the energy production 
pathways were affected by BA. In the introduction part has indicated that fast fibres 
were induced by BA. Data from microarray indicated that there was a metabolic 
response which reflected or perhaps induced this change as oxidative pathway was 
decreased. Decrease in genes associated with production of energy associated with 
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mitochondria (the down-regulated genes in citrate cycle pathway and Oxidative 
Phosphorylation). This suggested that the release of glucose from glycogen was not 
being oxidized. Therefore we could speculate that the effect of BA is to cause a 
degradation of glycogen which enters glycolysis as we have indication that enzymes 
(like enolase) in glycolysis are up regulated as well as PSAT. The effect of decreasing 
oxidative metabolism may force the carbon skeletons entering glycolysis to be 
utilized for synthesis of none essential amino acids which then help to induce the 
increase in muscle protein synthesis. In other words, there is a new hypotheses has 
been advanced that result on the action of beta-agonists is that the citrate cycle is 
repressed making more carbon available to go into amino acids (Figure 4.1).  
 
Figure 4.1 Affected energy production pathways (original photo supplied by Nelson 
and Cox.2005) 
There were many genes down-regulated by BA in citrate cycle pathway and oxidative 
phosphorylation pathway. This suggested that the whole processes of TCA and oxidative 
phosphorylation had been decreased by BA, and the release of glucose from glycogen was not 
being oxidized. Enolase and PSAT were up regulated and PSAT was associated with synthesis of 
serine. Hence, these suggested that carbon entering glycolysis was not oxidized, but utilized for 
synthesis of none essential amino acids (like serine). This trended to induce the increase in muscle 
protein synthesis and influenced muscle growth. 
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5 FUTURE WORK 
 
Since every kinds of high-throughput technology has error-prone nature. 
Microarray data always need to be confirmed by another independent method, for 
example qReal-time PCR. The aim is to validate that the changes of expression 
explored by microarray can be repeated by other methods (Clarke and Zhu 2006). For 
this project, the cross-species microarray has been used, therefore using qReal-time 
PCR to confirm the expression of the other target genes is very necessary. Besides this, 
what needs to be done is through doing qReal-time PCR to look at all the other genes 
of AKT1 pathway to see if the changes seen are associated with a protein synthesis 
down or up regulation. Also can use western blot to analyze the changes of specific 
proteins in post-translational level. After these, the metabolomic methods can be 
considered to confirm the pathways about energy metabolism. Such as metabolomic 
fingerprinting method (Liquid chromatography-mass spectrometry) and metabolomic 
profiling method. Finally, we should nearly observe that whether the improvement of 
microarray can supply a new kind of sheep array which suit to analysis ovine skeletal 
muscle. 
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6 CONCLUSION 
 
Recently, the control of lean and fat tissue deposition in livestock is widespread 
concerned by producers, consumers and environmentalists. Since increasing the ratio 
of lean to fat deposition can improve feed conversion efficiency and increase meat 
quality, thereby earn more profit to producers. Beside this, to improve feed conversion 
efficiency also can reduce grazing pressure, decrease nitrogenous excretion into the 
environment and supply more meat to the people with limited resources. Growth 
promoter (beta agonists and growth hormone) administration results in muscle fibre 
hypertrophy and changes in muscle fibre type composition, responses that are 
important in terms of human ageing and disease (such as sarcopenia and type 2 
diabetes), as well as animal growth efficiency.  
 
In order to study the reason of these effects, in this project, growth signaling 
pathways in skeletal muscle need to be identified. As current available sheep 
microarrays are more targeted to study genes involved in immune response, not 
suitable for studies on muscle growth and metabolism. And also the ovine does not 
have accomplished genome arrays available. Thereby, for this project the 
cross-species microarray had been used. Microarray data was analyzed using 
Ingenuity Pathway Analysis software and GeneSpring. The microarray analysis 
results were conformed by real-time quantitative RT-PCR.  
 
As the results of this project, there were 236 target genes up-regulated by 
beta-agonist relative to the control group, 209 target genes down-regulated by 
beta-agonist relative to the control group, 147 target genes up-regulated by growth 
hormone relative to the control group and 139 target genes down-regulated by growth 
hormone relative to the control group. These numbers also trended to suggest that the 
effect of beta-agonist to sheep skeletal muscle was stronger than the growth 
KRUPRQH¶V8VHGSDWKZD\Dnalysis of GeneSpring and IPA software, two predominant 
pathways which associated with the effects of beta-agonist had been identified. One 
was AKT1 pathway included most target genes or proteins, another one was PSAT1 
pathway. It included PSAT which associated with the synthesis of serine. Other three 
important pathway results, citrate cycle pathway, oxidative phosphorylation pathway 
and glycolysis pathway suggested a new hypotheses. The whole processes of TCA 
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and oxidative phosphorylation had been decreased by BA, and the carbon entering 
glycolysis was not oxidized, but used for synthesis of none essential amino acids (like 
serine). This trended to induce the increase in muscle protein synthesis and influenced 
muscle growth. The quantitative real-time PCR had been used to conform the target 
genes in PSAT1 pathway, the significant result provided us a high confidence to these 
cross-species microarray results.  
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8 APPENDICS  
 
Appendix 1 The summary of finally designed primers 
 
Gray shows exon boundaries. 
Target 
name 
Target 
sequence 
Exon 
bound
aries 
Amplicon 
length(bp
) 
Sequences  Penalt
y NO. 
Primer 
length(bp) 
FOXP1 Ovine 
EST 
YES 71 Forward primer: 
GGAGCATACCAACAGCAACGA  
Reverse primer: 
GTACAGGATGCACAGCTTGCA 
Probe: CGACAGCAGTCCGGGCAGATCC 
107 FOXP1F: 21 
FOXP1R: 21 
CLTA Ovine 
EST 
YES 91 Forward: 
GAAAGTATCCGTAAATGGAGAGAAGAG 
Reverse: TTTCTTTCCACTCCGCTTCCT 
Probe: ACGCTTGGAAGCCCTT GATGCCA 
213 CLTA F: 27 
CLTA R: 21 
RHBD
L1 
Ovine 
EST 
YES 111 Forward: 
CCTGACCGTCTCCATTACTGACA 
Reverse: ATCCCAGCCCAGTTCATGAC 
Probe: 
CTGTGTTCTGCACACCTGGCCAATG 
308 RHBDL1F: 
23 
RHBDL1R: 
20 
AKT1 Ovine 
cDNA 
YES 113 Forward: GAGGTCATCGTGGCCAAAGA 
Reverse: TCGTGCGTCTGGAAGGAGTA 
Probe: ACCCGTTCCTGACGGCCCTGAA 
315 AKT1F: 20 
AKT1R: 20 
CD44 Ovine 
EST 
YES 75 Forward: CCTGCAGGTACGGGTTCATAG 
Reverse: TGTTCGCAGCACAGATGGAA 
Probe: TGATTCCCCGGATCCACCCCA 
126 CD44F: 21 
CD44R: 20 
TUBA
1B 
Ovine 
EST 
YES 99 Forward: ACCAT GCGTGAGTGCATCTC 
Reverse: GGGCTGAATGCCGTGTTC 
Probe: 
AATGCCTGCTGGGAGCTCTACTGCC 
247 TUBA1BF: 
20 
TUBA1BR:1
8 
SUB1 Ovine 
EST 
YES 87 Forward: 
GAAATGAAACCAGGAAGAAAAGGTATA 
Reverse: 
TGCATCATCAATGTCAGAAATCTG 
Probe: 
CTTTAAATCCTGAACAATGGAGCCAGCT
GA 
196 SUB1F: 27 
SUB1R: 24 
ANK1 Ovine 
EST 
YES 94 Forward: GGTGACGGAGGAGCATTTCA 
Reverse: GGCTCCGGACGGGTCTAT 
Probe: 
CAACGTCGTCACCAAGAAGATCATTCG
C 
222 ANK1F: 20 
ANK1R:18 
C11orf
17 
Ovine 
EST 
YES 77 Forward: 
TCTCCCAGGAAAGAGAGAAGACA 
Reverse: 
TGTAGTTCATGTATTCAGCCATTGTTC 
Probe: 
145 C11orf17F: 
23 
C11orf17R: 
27 
 88 
ACACCCGACCCTCAGTGCTTCCTTC 
IFI44 Ovine 
EST 
YES 87 Forward: TTGTGCCTGCCTAGCTGTCA 
Reverse: 
CTGCCATACTTCTCAACCTGTTTG 
Probe: 
AGAGCAGCTACCCTCAGCTTCAGCCCT 
189 IFI44F: 20 
IFI44R:24 
CYP2C
9 
Ovine 
EST 
YES 118 Forward: AATCAGAGGCATGGCAAAGG 
Reverse: 
CTTCTGCTAGCTTGCTTATGGATTT 
Probe: TGCCACCTGGGCCCACTCCTCT 
345 CYP2C9F: 
20 
CYP2C9R: 
25 
 
CXCR
7 
Ovine 
EST 
NO 73 Forward: CGCCTCCTACAACGAGACCTA 
Reverse: CATGCTGATGAGCCACTCCTT 
Probe: TGCCGGGCCTTCTACCCCG 
117 CXCR7F: 21 
CXCR7R: 
21 
FOXO
3 
Ovine 
EST 
NO 71 Forward: TCGCAGTGACCCAATGATGT 
Reverse: 
GGAGCAAGTTCTGATTGACCAAA 
Probe: CTTTGCCGCCCAGCCTAACCAGG 
108 FOXO3F: 20 
FOXO3R: 
23 
TIAM1 Ovine 
EST 
NO 62 Forward: AGCCTCCGTGCAGAGCAT 
Reverse: ACGTCGCGTCATCCCTGTA 
Probe: CCAGACTCGGAAGACAGCCGGC 
63 TIAM1F: 18 
TIAM1R: 19 
 
CLYB
L 
Ovine 
EST 
YES 107 Forward: 
GGCAATGATGAAAAGAAGATAAACAAG 
Reverse: 
AATCTAGCTTCATCCTTTTTGTTCACA 
Probe: 
TTCCCTCCCTGAATGTAGACTGTGCGG 
299 CLYBLF: 27 
CLYBLR: 27 
DLST Ovine 
EST 
YES 79 Forward: 
GAACATCGGGAGAAAATGAACAG 
Reverse: GCATTGCGCAGGTGTTCTG 
Probe: CAGCGCATCGCTCAGCGTCTGA 
149 DLSTF: 23 
DLSTR: 19 
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Appendix 2 The meanings of all symbols in citrate cycle pathway 
 
Green shows down-regulated genes or proteins in the citrate cycle pathway. Red shows up-regulated genes or proteins in the citrate cycle pathway. 
Symbol  Synonym(s) 
1.1.1.37 (S)-malate:NAD oxidoreductase, L-malate dehydrogenase, L-malate-NAD+ oxidoreductase,malate (NAD) dehydrogenase, malic acid dehydrogenase, 
malic dehydrogenase, MDH, NAD-dependent malate dehydrogenase, NAD-dependent malic dehydrogenase, NAD-L-malate dehydrogenase, 
NAD-linked malate dehydrogenase, NAD-malate dehydrogenase, NAD-malic dehydrogenase, NAD-specific malate dehydrogenase 
1.1.1.41 beta-ketoglutaric-isocitric carboxylase, isocitrate:NAD oxidoreductase (decarboxylating), isocitric acid dehydrogenase, isocitric dehydrogenase , NAD 
dependent isocitrate dehydrogenase, 
NAD isocitrate dehydrogenase, NAD isocitric dehydrogenase, NAD-linked isocitrate dehydrogenase,NAD-specific isocitrate dehydrogenase 
1.1.1.42 
 
 
isocitrate (NADP) dehydrogenase, isocitrate (nicotinamide adenine dinucleotide phosphate) dehydrogenase,Isocitrate dehydrogen ase (NADP), 
isocitrate dehydrogenase (NADP-dependent), 
isocitrate:NADP oxidoreductase (decarboxylat ing), NADP isocitric dehydrogenase, NADP+ -linked isocitrate dehydrogenase, NADP-dependent 
isocitrate dehydrogenase, NADP-dependent 
isocitric dehydrogenase,NADP-linked isocitrate dehydrogenase, NADP-specific isocitrate dehydrogenase,oxalosuccinate decarboxylase, oxalsuccinic 
decarboxylase 
1.2.4.2 2-ketoglutarate dehydrogenase, 2-oxoglutarate dehydrogenase, 2-oxoglutarate:lipoamide 2-oxidoreductase (decarboxylating and 
acceptor-succinylating), 2-oxoglutarate:lipoate 
oxidoreductase, AKGDH, alpha-ketoglutarate dehydrogenase, alpha-ketoglutaric acid dehydrogenase, alpha-ketoglutaric dehydrogenase, 
alpha-oxoglutarate dehydrogenase, ketoglutaric dehydrogenase, OGDC, oxoglutarate decarboxylase, oxoglutarate dehydrogenase 
1.2.7.3 2-oxoglutarate-ferredoxin oxidoreductase, 2-oxoglutarate:ferredoxin 2-oxidoreductase (CoA-succinylating), alpha-ketoglutarate synthase, 
alpha-ketoglutarate-ferredoxin oxidoreductase, oxoglutarate synthase 
1.3.5.1 complex II, fumarate reductase complex, menaquinol:fumarate oxidoreductase, succinate dehydrogenase complex, succinate:ubiquinone 
oxidoreductase, succinic dehydrogenase 
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1.3.99.1 Complex II, Succinate INT Dehydrogenase 
1.8.1.4 dehydrolipoate dehydrogenase, diaphorase, dihydrolipoamide:NAD oxidoreductase, dihydrolipoic dehydrogenase, dihydrolipoyl dehydrogenase, 
dihydrothioctic dehydrogenase, LDP-Glc, LDP-Val, lipoamide dehydrogenase (NADH), lipoamide oxidoreductase (NADH), lipoamide reductase, 
lipoamide reductase (NADH2), lipoate dehydrogenase, lipoic acid dehydrogenase, lipoyl dehydrogenase 
2.3.1.61 dihydrolipoamide succinyltransferase, dihydrolipoic transsuccinylase, dihydrolipolyl transsuccinylase, dihydrolipoyl t ranssuc cinylase, lipoate 
succinyltransferase (Escherichia coli), lipoic t ranssuccinylase, lipoyl transsuccinylase, succinyl-CoA:dihydrolipoamide S-succinyltransferase, 
succinyl-CoA:dihydrolipoate S-succinyltransferase 
2.3.3.1 (R)-citric synthase, acetyl-CoA:oxaloacetate C-acetyltransferase [thioester-hydrolysing, (pro-S)-carboxymethyl forming], citrate condensing enzyme, 
citrate oxaloacetate-lyase 
[(pro-3S)-CH2COO-acetyl-CoA], citrate oxaloacetate-lyase, CoA-acetylating, citrate synthase, citrate synthetase, citric synthase, citric-condensing 
enzyme, citrogenase, condensing enzyme, oxalacetic transacetase, oxaloacetate transacetase 
2.3.3.8 acetyl-CoA:oxaloacetate acetyltransferase (isomerizing, ADP-phosphorylating), acetyl-CoA:oxaloacetate C-acetyltransferase 
[(pro-S)-carboxymethyl-forming, ADP-phosphorylating], adenosine triphosphate citrate lyase, ATP citrate (pro-S)-lyase, ATP-citric lyase, ATP:cit rate 
oxaloacetate-lyase [(pro-S)-CH2COO-&gt;acetyl-CoA] (ATP-dephosphorylating), ATP:citrate oxaloacetate-lyase [(pro-S)-CH2COO-acetyl-CoA] 
(ATP-dephosphorylating), citrate cleavage enzyme, cit rate-ATP lyase, citric cleavage enzyme  
2.8.3.10 acetyl-CoA:citrate CoA-transferase 
3.1.2.3 succinyl coenzyme A deacylase, succinyl coenzyme A hydrolase, succinyl-CoA acylase 
4.1.1.32 GTP:oxaloacetate carboxy-lyase (transphosphorylating), PEP carboxylase, phosphoenolpyruvate carboxykinase, phosphoenolpyruvate carboxylase, 
phosphoenolpyruvic carboxykinase, phosphoenolpyruvic carboxykinase (GTP), phosphoenolpyruvic carboxylase (GTP), phosphopyruva te (guanosine 
triphosphate) carboxykinase, phosphopyruvate carboxylase, phosphopyruvate carboxylase (GTP)  
4.1.1.49 ATP:oxaloacetate carboxy-lyase (transphosphorylating), PEP carboxykinase, PEP carboxylase, PEPCK, PEPCK (ATP), PEPK, phosphoenolpyruvate 
carboxykinase, phosphoenolpyruvate 
carboxylase, phosphoenolpyruvate carboxylase (ATP), phosphoenolpyruvic carboxykinase, phosphoenolpyruvic carboxylase, phospho pyruvate 
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carboxykinase, phosphopyruvate carboxykinase (adenosine triphosphate), phosphopyruvate carboxylase (ATP) 
4.1.3.34 (3S)-citry l-CoA oxaloacetate-lyase 
4.1.3.6 citrase, citratase, citrate aldolase, citrate lyase, citrate oxaloacetate-lyase, citrate oxaloacetate-lyase [(pro-3S)-CH2COO-acetate], citric aldolase, 
citrides molase, citritase 
4.2.1.2 (S)-malate hydro-lyase, fumarase, L-malate hydro-lyase 
4.2.1.3 Acon, Aconitate hydratase, cis-aconitase, citrate(isocitrate) hydro-lyase 
6.2.1.18 citrate:CoA ligase (ADP-forming) 
6.2.1.4 succinate:CoA ligase (GDP-forming), succinyl-CoA synthetase (GDP-forming) 
6.2.1.5 succinate:CoA ligase (ADP-forming), Succinic Thiokinase, succinyl-CoA synthetase (ADP-forming) 
6.4.1.1 pyruvate:carbon-dioxide ligase (ADP-forming), pyruvic carboxylase 
 
Appendix 3 The meanings of all symbols in oxidativephosphorylation pathway 
 
Green shows down-regulated genes or proteins in the oxidative phosphorylation pathway. Red shows up-regulated genes or proteins in the oxidative phosphorylation 
pathway. 
Symbol  Synonym(s) 
1.10.2.2 
coenzyme Q-cytochrome c reductase, coenzyme QH2-cytochrome c reductase, CoQH2-cytochrome c oxidoreductase, dihydrocoenzyme 
Q-cytochrome c reductase, mitochondrial electron transport complex III, QH2:cytochrome c oxidoreductase, reduced coenzyme Q-cytochrome c 
reductase, reduced ubiquinone-cytochrome c oxidoreductase, reduced ubiquinone-cytochrome c reductase, complex III (mitochondrial electron 
transport), ubihydroquinol:cytochrome c oxidoreductase, ubiquinol-cytochrome c oxidoreductase, ubiquinol-cytochrome c-2 oxidoreductase, 
ubiquinol-cytochrome c1 oxidoreductase, ubiquinol-cytochrome c2 reductase, ubiquinol:ferricytochrome-c oxidoreductase, ubiquinone-cytochrome 
b-c1 oxidoreductase, ubiquinone-cytochrome c oxidoreductase, ubiquinone-cytochrome c reductase 
1.3.5.1 complex II, fumarate reductase complex, menaquinol:fumarate oxidoreductase, succinate dehydrogenase complex, succinate:ubiquinone 
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oxidoreductase, succinic dehydrogenase 
1.3.99.1 Complex II, Succinate INT Dehydrogenase 
1.6.5.3 
coenzyme Q reductase, complex 1 dehydrogenase, complex I (electron  transport chain), complex I (mitochondrial electron transport), complex I 
(NADH:Q1 oxidoreductase), dihydronicotinamide adenine dinucleotide-coenzyme Q reductase, DPNH-coenzyme Q reductase, DPNH-ubiquinone 
reductase, electron transfer complex I, mitochondrial electron transport complex 1, mitochondrial electron transport complex I, NADH coenzyme 
Q1 reductase, NADH-coenzyme Q oxidoreductase, NADH-coenzyme Q reductase, NADH-CoQ oxidoreductase, NADH-CoQ reductase, NADH-Q6 
oxidoreductase, NADH-ubiquinone oxidoreductase, NADH-ubiquinone reductase, NADH-ubiquinone-1 reductase, NADH2:ubiquinone 
oxidoreductase, NADH:ubiquinone oxidoreductase complex, reduced nicotinamide adenine dinucleotide -coenzyme Q reductase, type 1 
dehydrogenase, ubiquinone reductase 
1.6.99.3 
beta-NADH dehydrogenase dinucleotide, cytochrome c reductase, diaphorase, dihydrocodehydrogenase I dehydrogenase, dihydronicotinamide 
adenine dinucleotide dehydrogenase, diphosphopyri3633se, DPNH d iaphorase, NADH cytochrome C reductase, NADH diaphorase, NADH 
hydrogenase, NADH oxidoreductase, NADH-menadione oxidoreductase, NADH2:(acceptor) oxidoreductase, NADH:cytochrome c oxidoreductase, 
reduced diphosphopyridine nucleotide diaphorase, type 1 dehydrogenase 
1.6.99.5 
D-diaphorase, DPNH-menadione reductase, NADH-quinone oxidoreductase, NADH2:(quinone-acceptor) oxidoreductase, reduced nicotinamide 
adenine dinucleotide (quinone) dehydrogenase 
1.9.3.1 complex IV (mitochondrial electron transport), COX, Cytochrome Aa3, Mitochondrial Complex IV, respiratory chain complex IV 
2.7.4.1 ATP:polyphosphate phosphotransferase, polyphosphoric acid kinase 
3.6.1.1 diphosphate phosphohydrolase 
3.6.3.10 (K+ + H+)-ATPase, ATP phosphohydrolase (H+/K+-exchanging), H+-K+-ATPase, H,K-ATPase 
3.6.3.14 
ATP phosphohydrolase (H+-transporting), ATP synthase, bacterial Ca2+/Mg2+ ATPase, chloroplast ATPase, coupling factors (F0, F1 and CF1), 
F1-ATPase, FoF1-ATPase, H+-transporting ATPase, mitochondrial ATPase 
3.6.3.6 
ATP phosphohydrolase, ATP phosphohydrolase (H+-export ing), proton-translocating ATPase, yeast plasma membrane ATPase, yeast plasma 
membrane H+-ATPase 
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ADP 
20398-34-9, 58-64-0, 9-beta-D-arab inofuranosyladenine 5'-diphosphate, adenosine 5'-(trihydrogen diphosphate), adenosine diphosphate, 
C10H15N5O10P2, [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate 
ATP 
56-65-5, 9-beta-D-arabinofuranosyladenine 5'-triphosphate, adenosine 5'-(tetrahydrogen triphosphate), adenosine 5'-triphosphate, adenosine 
triphosphate, ATP4-, C10H16N5O13P3, [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan -2-yl]methoxy -hydroxyphosphoryl] 
phosphono hydrogen phosphate 
Diphosphate 14000-31-8, diphosphate, diphosphate(4-), inorganic pyrophosphate, O7P2-4, phosphonato phosphate, PPi, pyrophosphate ion 
Fumarate (E)-but-2-enedioic acid, 110-17-8, 2-butenedioic acid (2E)-, C4H4O4, fumarate  
H+ 12408-02-5, 12586-59-3, H+, hydrogen ion, hydron, proton 
H2O 7732-18-5, H20, H2O, oxidane  
NAD+ 
53-84-9, adenosine 5'-(t rihydrogen diphosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt, beta-NAD+, 
beta-nicotinamide adenine d inucleotide+, C21H28N7O14P2+, NAD, 
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 
[(2R,3S,4R,5R)-5-(3-carbamoylpyridin -1-ium-1-yl)-3,4-d ihydroxyoxolan-2-yl]methyl hydrogen phosphate 
NADH 
58-68-4, adenosine 5'-(trihydrogen diphosphate), P'-5'-ester with 1,4-d ihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide, beta-NADH, 
C21H29N7O14P2, dihydronicotinamide-adenine dinucleotide, NADH2, nicotinamide dinucleotide, 
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 
[(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyrid in-1-yl)-3,4-d ihydroxyoxolan-2-yl]methyl hydrogen phosphate 
Oxygen 7782-44-7, d ioxygen, molecu lar oxygen, O2 
Phosphate 14265-44-2, inorganic phosphate, O4P-3, phosphate, phosphate ion, phosphate(3-), Pi 
Succinate 
1,2-ethanedicarboxylic acid, 1,4-butanedioic acid, 110-15-6, 56-14-4, amber acid, asuccin, butanedioate, butanedioic acid, C4H6O4, 
ethylenesuccinic acid, katasuccin, potassium succinate, succinate, wormwood acid 
Triphosphate 14127-68-5, O10P3-5, triphosphate, [oxido(phosphonatooxy)phosphoryl] phosphate 
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Ubiquinol 56275-39-9, C14H20O4(C5H8)n, CoQH2, QH2, ubihydroquinone, ubiquinol, ubiquinone hydroquinone 
Ubiquinone 1339-63-5, C14H18O4(C5H8)n, coenzyme Q, ubiquinones 
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